U.S. Stem Cell (USRM) 10-Q 16 Jul 21 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Jul. 15, 2021
Document Information Line Items
Entity Registrant Name	U.S. STEM CELL, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		452,413,153
Amendment Flag	false
Entity Central Index Key	0001388319
Entity Current Reporting Status	No
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Interactive Data Current	Yes

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 81,228	$ 0
Accounts receivable, net	21,469	48,208
Inventories	5,418	8,096
Prepaid expenses and other current assets	10,000	10,000
Total current assets	118,115	66,304
Investments	0	23,539
Total assets	118,115	89,843
Current liabilities:
Bank overdraft	0	1,520
Accounts payable	1,231,623	1,187,989
Accrued expenses	1,379,821	1,115,526
Advances - related parties	797,040	511,744
Deferred revenue, current portion	23,000	23,800
Deferred gain on sale of equipment, current portion	0	21,474
Deposits	465,286	465,286
Notes payable - related parties	3,733,404	2,757,442
Notes payable, current portion, net of debt discount of $9,501 and $9,057, respectively	1,400,910	1,297,477
Promissory note payable, net of debt discount of $0 and $29,296, respectively	1,397,762	1,368,467
Convertible notes payable, net of debt discount of $6,221 and $0, respectively	38,779	0
Total current liabilities	10,467,625	8,750,725
Long-term liabilities:
Deferred revenue	60,250	62,500
Notes payable, net of debt discount of $34,091 and $41,391, respectively	769,741	756,014
Total long-term liabilities	829,991	818,514
Total liabilities	11,297,616	9,569,239
Commitments and contingencies (See Note 13)
Stockholders' deficit:
Preferred stock, par value $0.001; 20,000,000 shares authorized, -0- issued and outstanding	0	0
Common stock, par value $0.001; 2,000,000,000 shares authorized, 429,702,662 and 417,724,767 shares issued and outstanding, respectively	429,703	417,725
Additional paid-in capital	124,315,620	123,726,894
Accumulated deficit	(135,924,824)	(133,624,015)
Total stockholders' deficit	(11,179,501)	(9,479,396)
Total liabilities and stockholders' deficit	$ 118,115	$ 89,843

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parentheticals) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Debt discount (in Dollars)	$ 43,592	$ 50,448
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	429,702,662	417,724,767
Common stock, shares outstanding	429,702,662	417,724,767
Notes Payable, Other Payables [Member]
Debt discount (in Dollars)	$ 34,091	$ 41,391
Notes Payable, Other Payables [Member]
Debt discount (in Dollars)	9,501	9,057
Promissory Note [Member]
Debt discount (in Dollars)	0	29,296
Convertible Notes Payable [Member]
Debt discount (in Dollars)	$ 6,221	$ 0

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue:
Revenue	$ 64,647	$ 156,591	$ 161,793	$ 2,763,385
Cost of sales	18,576	137,366	53,550	1,165,459
Gross profit	46,071	19,225	108,243	1,597,926
Operating expenses:
Research and development	0	0	0	263
Selling, general and administrative	1,039,352	1,616,970	2,068,245	3,628,652
Pre-litigation settlement	0	0	0	500,000
Total operating expenses	1,039,352	1,616,970	2,068,245	4,128,915
Loss from operations	(993,281)	(1,597,745)	(1,960,002)	(2,530,989)
Other income (expenses):
Gain (loss) on settlement of accounts payable and accrued interest, net	(204)	33,203	277	21,892
Gain on sale of equipment	0	32,211	21,474	96,634
Miscellaneous income	0	11,000	0	11,069
Income (loss) from equity investments	(9,718)	(33,478)	(23,539)	93,778
Interest expense	(152,572)	(91,140)	(339,019)	(850,677)
Total other income (expenses)	(162,494)	(48,204)	(340,807)	(627,304)
Net loss before income taxes	(1,155,775)	(1,645,949)	(2,300,809)	(3,158,293)
Income taxes (benefit)	0	0	0	0
NET LOSS	$ (1,155,775)	$ (1,645,949)	$ (2,300,809)	$ (3,158,293)
Net loss per common share, basic and diluted (in Dollars per share)	$ 0	$ 0	$ (0.01)	$ (0.01)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	429,684,176	396,637,920	427,207,208	392,029,562
Product [Member]
Revenue:
Revenue	$ 44,970	$ 28,160	$ 116,347	$ 299,826
Service [Member]
Revenue:
Revenue	19,677	127,456	45,446	2,412,808
Management Fees-related Party [Member]
Revenue:
Revenue	$ 0	$ 975	$ 0	$ 50,751

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2018		$ 378,077	$ 122,528,391	$ (129,788,678)	$ (6,882,210)
Balance (in Shares) at Dec. 31, 2018		378,076,976
Common stock issued in settlement		$ 16,167	296,027		312,194
Common stock issued in settlement (in Shares)		16,166,984
Common stock issued for services		$ 3,500	82,850		86,350
Common stock issued for services (in Shares)		3,500,000
Contribution to equity investment			15,265		15,265
Stock based compensation			512,882		512,882
Net loss				(3,158,293)	(3,158,293)
Balance at Sep. 30, 2019		$ 397,744	123,435,415	(132,946,971)	(9,113,812)
Balance (in Shares) at Sep. 30, 2019		397,743,960
Balance at Jun. 30, 2019		$ 393,695	123,231,001	(131,301,022)	(7,676,326)
Balance (in Shares) at Jun. 30, 2019		393,694,820
Common stock issued in settlement		$ 4,049	29,964		34,013
Common stock issued in settlement (in Shares)		4,049,140
Stock based compensation			174,450		174,450
Net loss				(1,645,949)	(1,645,949)
Balance at Sep. 30, 2019		$ 397,744	123,435,415	(132,946,971)	(9,113,812)
Balance (in Shares) at Sep. 30, 2019		397,743,960
Balance at Dec. 31, 2019	$ 0	$ 417,725	123,726,894	(133,624,015)	(9,479,396)
Balance (in Shares) at Dec. 31, 2019	0	417,724,767
Common stock issued in settlement		$ 7,978	36,390		44,368
Common stock issued in settlement (in Shares)		7,977,895
Common stock issued for services		$ 4,000	12,000		$ 16,000
Common stock issued for services (in Shares)		4,000,000			4,000,000
Beneficial conversion feature recognized on convertible note			15,000		$ 15,000
Stock based compensation			525,336		525,336
Net loss				(2,300,809)	(2,300,809)
Balance at Sep. 30, 2020	$ 0	$ 429,703	124,315,620	(135,924,824)	(11,179,501)
Balance (in Shares) at Sep. 30, 2020	0	429,702,662
Balance at Jun. 30, 2020	$ 0	$ 428,002	124,132,196	(134,769,049)	(10,208,851)
Balance (in Shares) at Jun. 30, 2020	0	428,001,981
Common stock issued in settlement		$ 1,701	8,504		10,205
Common stock issued in settlement (in Shares)		1,700,681
Stock based compensation			174,920		174,920
Net loss				(1,155,775)	(1,155,775)
Balance at Sep. 30, 2020	$ 0	$ 429,703	$ 124,315,620	$ (135,924,824)	$ (11,179,501)
Balance (in Shares) at Sep. 30, 2020	0	429,702,662

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,300,809)	$ (3,158,293)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	0	154,956
Bad debt (recoveries)	0	30,869
Interest and amortization of debt discount	309,219	141,296
(Gain) loss on settlement of accounts payable and accrued interest	(277)	(21,892)
Gain on sale of equipment	(21,474)	(96,634)
Related party notes payable issued for services rendered	975,962	800,000
Loss (income) on equity investments	23,539	(93,778)
Note payable issued in pre-trial settlement	0	500,000
Stock-based compensation	541,336	586,382
Changes in operating assets and liabilities:
Accounts receivable	26,739	(33,079)
Inventories	2,678	46,864
Accounts payable	79,134	269,070
Accrued expenses	9,152	(4,507)
Deferred revenue	(3,050)	(112,390)
Net cash used in operating activities	(357,851)	(991,136)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from equity investments	0	166,833
Net cash provided by investing activities	0	166,833
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments for overdraft protection	(1,520)	0
Proceeds from related party advances	285,296	140,000
Repayments of related party notes	0	(213,739)
Proceeds from notes payable	150,000	0
Repayments of notes payable	(39,697)	(381,000)
Proceeds from convertible note payable	45,000	0
Net cash provided by (used in) financing activities	439,079	(454,739)
Net increase (decrease) in cash and cash equivalents	81,228	(1,279,042)
Cash and cash equivalents, beginning of period	0	1,357,146
Cash and cash equivalents, end of period	81,228	78,104
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest paid	29,800	633,859
Income taxes paid	0	0
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued in settlement of notes payable	44,368	312,194
Beneficial conversion feature recognized on convertible note	15,000	0
Equity contributed to investment	0	15,265
Record right-to-use assets and related lease liability	$ 0	$ 383,351

NATURE OF OPERATIONS

NATURE OF OPERATIONS	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Nature of Operations [Text Block]	NATURE OF OPERATIONS Overview U.S. Stem Cell, Inc. was incorporated under the laws of the State of Florida in August 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. The business includes the development of proprietary cell therapy products as well as revenue generating physician and patient-based regenerative medicine/cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of cell therapy clinics. To date, the Company has not generated significant revenues in that they remain less than their total operating expenses, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a research and development business enterprise. Basis of Presentation The interim unaudited condensed financial statements included herein reflect all material adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) which, in the opinion of the Company’s management, are ordinary and necessary for a fair presentation of results for the interim periods. Certain information and footnote disclosures required under generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company’s management believes the disclosures are adequate to make the information presented not misleading. The condensed balance sheet information as of December 31, 2019 was derived from the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2019 (“2019 Annual Report”), filed with the SEC pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on July 15, 2021. These interim unaudited condensed financial statements should be read in conjunction with the 2019 Annual Report. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the entire fiscal year or for any other period.

GOING CONCERN AND MANAGEMENT'S

GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 GOING CONCERN AND MANAGEMENT S LIQUIDITY PLANS The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, as of September 30, 2020, the Company had cash on hand of $81,228 and a working capital deficit (current liabilities in excess of current assets) of $10,349,510. During the nine months ended September 30, 2020, the net loss was $2,300,809 and net cash used in operating activities was $357,851. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for one year from the issuance of the unaudited condensed financial statements. The Company’s primary source of operating funds has been from revenue generated from sales with additional cash proceeds from the sale of common stock and the issuances of promissory notes and other debt. The Company has experienced net losses from operations since inception, but it expects these conditions to improve in the future as it develops its business model. The Company had a stockholders’ deficit of 11,179,501 at September 30, 2020 and requires additional financing to fund future operations. The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern. Along with diversifying the portfolio of products distributed by the Company, including equipment and biologics, it is the intention of the Company management to both continue to adhere to the Court Order (see Note 13) as well as re-establish its good standing with the Agency (FDA). These points are not mutually exclusive nor negotiable and management believes that there are still business and patient goodness opportunities while still abiding by all legal requirements As a result, management shall be continuing with the development of US Stem Cell Training, Inc., an operating division of the Company, that is a content developer of regenerative medicine/cell therapy informational and training materials for physicians and patients and complies with both requirements--as well as Vetbiologics, an operating division of the Company, that is a veterinary regenerative medicine company committed to providing veterinarians with the ability to deliver the highest quality regenerative medicine therapies to dogs, cats and horses.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	NOTE 3 SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from these estimates. Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable, accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Cash The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts. Credit is extended to customers based on an evaluation of their financial condition, industry reputation, and other judgmental factors considered by the Company’s management. The Company generally does not require collateral or other security interest to support accounts receivable. Based on trends and specific factors, the customer’s credit terms may be modified, including required payment upon delivery. The Company performs regular on-going credit evaluations of its customers as deemed relevant. As events, trends, and circumstance warrant, the Company’s management estimates the amounts that are more likely than not to be uncollectible. These amounts are recognized as bad debt expense and are reflected within selling, general, administrative and other expenses on the Company’s accompanying statement of operations. Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of September 30, 2020 and December 31, 2019, the allowance for doubtful accounts was $13,203. Inventories Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs. Investments The Company follows Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 49.9% member interest ownerships of U.S. Stem Cell Clinic, LLC and Regenerative Wellness Clinic, LLC, respectively, and its 49% member interest ownership of U.S. Stem Cell Clinic of the Villages utilizing the equity method of accounting (See Note 5). Revenue Recognition Effective January 1, 2018, the Company recognizes revenue in accordance with Accounting Standards Codification 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client. The Company’s primary sources of revenue are from the sale of test kits and equipment, training services, patient treatments, laboratory services and cell banking. Revenues for kits and equipment sold are not recorded until kits and equipment are received by the customer. Revenues from in-person trainings are recognized when the training occurs and revenues from on demand online trainings are recognized when the customer purchases the rights to the training course. Any cash received as a deposit for trainings are recorded by the Company as a liability. Patient treatments and laboratory services revenue are recognized when those services have been completed or satisfied. Revenues for cell banking are accounted for as multiple performance obligations as described in ASC 606 and addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. Because the Company sells its services separately, on more than a limited basis and at a price within a narrow range, the Company was able to allocate revenue based on stand-alone pricing. The multiple performance obligations include stem cell banking, dose retrieval and yearly storage fees. Revenues for stem cell banking and dose retrieval is recognized at the point of service and revenues for the yearly storage fees is recognized over the term of the banking contract, which is typically one year with annual renewals. At September 30, 2020 and December 31, 2019, the Company had deferred revenues of $83,250 and $86,300, respectively, which includes $63,250 and $65,500, respectively, for the Intellectual Property Licensing Agreement. Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $0 for the three and nine months ended September 30, 2020, respectively; and $0 and $263 for the three and nine months ended September 30, 2019, respectively. Stock-Based Compensation Stock-based compensation expense is measured at the grant date fair value of the award and is expensed over the requisite service period. For stock-based awards to employees, non-employees and directors, the Company calculates the fair value of the award on the date of grant using the Black-Scholes option pricing model. Determining the fair value of stock-based awards at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based awards represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. Net Loss per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted income (loss) per share as of September 30, 2020 and 2019 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2020 2019 Options 111,119,914 121,038,655 Warrants 1,110,468 1,112,251 Convertible note 11,260,433 - Total potentially dilutive shares 123,490,815 122,150,906 Recent Accounting Pronouncements FASB Accounting Standards Updates (“ASU”) 2017-04 (Topic 350), “Intangibles – Goodwill and Others” – Issued in January 2017, ASU 2017-04 simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. This guidance was effective for the Company in the first fiscal quarter of 2020. The adoption of this standard did not have a material impact on the Company’s financial statements and related disclosures. In February 2016, the FASB established ASC Topic 842, Leases (Topic 842), by issuing ASU No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company adopted the new standard on January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. The new standard had a material effect on the Company’s financial statements. The most significant effects of adoption relate to (1) the recognition of new ROU assets and lease liabilities on its balance sheet for real estate operating leases; and (2) providing significant new disclosures about its leasing activities. Upon adoption, the Company recognized additional operating lease liabilities, net of deferred rent, of approximately $57,000 based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases. The Company also recognized corresponding ROU assets of approximately $57,000. On October 24, 2019, the Company entered into an Assignment and Assumption of Lease by and between the Company, American Cell Technology, LLC, and Sawgrass Business Plaza, LLC. Subsequently, the Company relocated to a new location within the same city and entered into a month-to-month lease. Accordingly, the right of use assets and lease liabilities were eliminated. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. Beginning in 2019, the Company changed to its disclosed lease recognition policies and practices, as well as to other related financial statement disclosures due to the adoption of this standard. FASB ASU No. 2018-07 (Topic 718), “Compensation – Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting” – Issued in June 2018, ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606. The Company adopted the new standard on January 1, 2019. The adoption of this guidance did not have a material impact on the Company’s financial condition or results of operations. In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on accounting for convertible debt instruments by removing the separation models for: (1) convertible debt with a cash conversion feature; and (2) convertible instruments with a beneficial conversion feature. As a result, the Company will not separately present in equity an embedded conversion feature in such debt. Instead, we will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. We expect the elimination of these models will reduce reported interest expense and increase reported net income for the Company’s convertible instruments falling under the scope of those models before the adoption of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will be no longer available. The provisions of ASU 2020-06 are applicable for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements. In August 2018, the FASB issued Accounting Standards Update (“ASU”) 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”). ASU 2018-13 removes certain disclosure requirements, including the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels, and the valuation processes for Level 3 fair value measurements. ASU 2018-13 also adds disclosure requirements, including changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements, and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. The amendments on changes in unrealized gains and losses, and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. This guidance was effective for the Company in the first fiscal quarter of 2020. The adoption of this standard did not have a material impact on the Company’s financial statements and related disclosures. There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 PROPERTY AND EQUIPMENT Property and equipment as of September 30, 2020 and December 31, 2019 is summarized as follows: September 30, December 31, Furniture, fixtures and equipment $ 5,598 $ 5,598 Computer equipment 1,809 1,809 Property and equipment, cost 7,407 7,407 Less: accumulated depreciation and amortization (7,407 ) (7,407 ) Property and equipment, net $ - $ - As a consequence of the Court Order (see Note 13 “Government Claim”), the Company resolved to divest itself of certain equipment and other assets (the “Equipment Assets”) used in connection with the Company’s human tissue banking business, but consistent however with the requirements of the Court Order, and to adjust the business plan and operations to accommodate this potential divesture. To facilitate the above, the Company entered into a Termination and Release Agreement and a Letter Agreement intended to divest itself of certain equipment and other assets underlying the related equipment lease transaction. In addition, on October 24, 2019, the Company entered into an Assignment and Assumption of Lease by and between the Company, American Cell Technology, LLC, and Sawgrass Business Plaza, LLC. Subsequently, the Company relocated to a new location within the same city and entered into a month-to-month lease. As part of the termination of the operating lease, the Company left certain property and equipment (all of which had been fully depreciated) at the old location. In connection with the sale of the lab, medical and other equipment, the Company realized a gain on sale of equipment of $386,535. The gain is recognized ratably over the term of the lease to operations. During the three and nine months ended September 30, 2020, the Company recognized $0 and $21,474, respectively; and $32,211 and $96,634 during the three and nine months ended September 30, 2019, respectively, as gain on sale of equipment. As of September 30, 2020 and December 31, 2019, deferred gain on sale of equipment was $0 and $21,474, respectively. Depreciation expense was $0 for the three and nine months ended September 30, 2020, respectively. Depreciation expense was $51,652 and $154,956, of which $51,652 and $154,956 was included in cost of sales, for the three and nine months ended September 30, 2019, respectively.

INVESTMENTS

INVESTMENTS	9 Months Ended
	Sep. 30, 2020
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 5 INVESTMENTS U.S. Stem Cell Clinic, LLC The investment in U.S. Stem Cell Clinic, LLC is comprised of a 49.9% (increased from 33.3% on January 29, 2019) member interest ownership and is accounted for using the equity method of accounting. The Company’s income (loss) earned by U.S. Stem Cell Clinic, LLC member interest was ($9,718) and ($23,539) for the three and nine months ended September 30, 2020, respectively; and ($51,514) and $51,514 for the three and nine months ended September 30, 2019, respectively (inception to date income of $599,921) and is included in other income (expense) in the accompanying Statements of Operations. In addition, during the nine months ended September 30, 2020 and 2019, the Company received distributions totaling $0 and $64,870, respectively, from U.S. Stem Cell Clinic, LLC (inception to date of $663,870). The carrying value of the investment at September 30, 2020 and December 31, 2019 is $0 and $23,539, respectively (See also Note 16; In March, 2021, the Company divested its entire interest in U.S. Stem Cell Clinic, LLC). At September 30, 2020 and December 31, 2019, accounts receivable for sales of product and services to U.S. Stem Cell Clinic, LLC was $28,763. Revenues earned from sales to U.S. Stem Clinic, LLC for the three and nine months ended September 30, 2020 were $0 and $1,441, respectively; and $33,614 and $329,003 for the three and nine months ended September 30, 2019, respectively. In January 2019, a member of U.S. Stem Cell Clinic, LLC contributed 16.6% of his ownership interest to the Company increasing the Company’s member interest from 33.3% to 49.9%. The Company recorded the contribution to equity of $4,435. An affiliate of one of the Company’s officers is a minority investor in the U.S. Stem Cell Clinic, LLC. Regenerative Wellness Clinic, LLC The investment in Regenerative Wellness Clinic, LLC is comprised of a 49.9% (increased from 33.3% on January 29, 2019) member interest ownership and is accounted for using the equity method of accounting. The Company has provided technical expertise, but no cash investment with Regenerative Wellness Clinic, LLC’s startup in 2017. The Company’s income earned by Regenerative Wellness Clinic, LLC member interest was $0 for the three and nine months ended September 30, 2020; and ($2,910) and $69,345 for the three and nine months ended September 30, 2019, respectively (inception to date income of $113,047) and is included in other income (expense) in the accompanying Statements of Operations. In addition, during the nine months ended September 30, 2020 and 2019, the Company received distributions totaling $0 and $101,963, respectively, from Regenerative Wellness Clinic, LLC (inception to date of $101,963). The carrying value of the investment at September 30, 2020 and December 31, 2019 is $0. In October 2019, the Company divested its entire interest in U.S. Stem Cell Clinic, LLC. At December 31, 2019, accounts receivable for sales of products and services to Regenerative Wellness Clinic, LLC was $0. Revenues earned from sales to Regenerative Wellness Clinic, LLC for the three and nine months ended September 30, 2019 was $16,637 and $132,984, respectively. In January 2019, a member of Regenerative Wellness Clinic, LLC contributed 16.6% of his ownership interest to the Company increasing the Company’s member interest from 33.3% to 49.9%. The Company recorded the contribution to equity of $10,830. An affiliate of one of the Company’s officers is an investor in the Regenerative Wellness Clinic, LLC. U.S. Stem Cell of the Villages LLC On January 30, 2018, Greg Knutson, a director of the Company (“Knutson”) and the Company agreed to open and operate a regenerative medicine/cell therapy clinic providing cellular treatments for patients afflicted with neurological, autoimmune, orthopedic and degenerative diseases in Florida. To that end, U.S. Stem Cell Clinic of The Villages LLC (the “LLC”) was formed January 30, 2018. Knutson provided the Company with the sum of Three Hundred Thousand Dollars ($300,000) (the “Investment”) to be utilized for the formation and initial operation of the LLC. Currently, Knutson holds a 51% member interest in the LLC and the Company holds a 49% member interest. The Company will provide operating assistance as well as management services, the latter to be compensated at fee of five percent (5%) of the LLC gross revenues. As of December 31, 2018, upon completion of U.S. Stem Cell of the Villages LLC, the Company received $189,909 from Greg Knutson, the holder of the 51% member interest. Accordingly, this was recognized as additional paid-in capital. Subsequently, the Company contributed $86,750 as its initial investment in the U.S. Stem Cell of the Villages, LLC. The Company’s 49% income (loss) incurred by U.S. Stem Cell of the Villages LLC member interest was $0 for the three and nine months ended September 30, 2020; and ($9,931) and ($27,081) for the three and nine months ended September 30, 2019, respectively (inception to date loss of $23,050) and is included in other income (expense) in the accompanying Statements of Operations. In addition, during the nine months ended September 30, 2020 and 2019, the Company received distributions totaling $0 from U.S. Stem Cell of the Villages LLC. The carrying value of the investment at September 30, 2020 and December 31, 2019 was $0. At September 30, 2020 and December 31, 2019, accounts receivable for sales of products and services to U.S. Stem Cell of the Villages LLC was $0. Revenues earned from sales to U.S. Stem Cell of the Villages LLC for the three and nine months ended September 30, 2020 was $0, respectively; and $9,975 and $140,328 for the three and nine months ended September 30, 2019, respectively. During the three and nine months ended September 30, 2020, the Company received $0; and $975 and $50,751 for the three and nine months ended September 30, 2019, respectively, in management fees from the LLC. As of the date of this filing, US Stem Cell Clinic of the Villages, LLC is currently dormant.

RIGHT TO USE ASSETS AND LEASE L

RIGHT TO USE ASSETS AND LEASE LIABILITY	9 Months Ended
	Sep. 30, 2020
Disclosure Text Block [Abstract]
Lessee, Operating Leases [Text Block]	NOTE 6 RIGHT TO USE ASSETS AND LEASE LIABILITY The Company leased its headquarters in Sunrise, Florida which consisted of 4,860 square feet of space at a rate of approximately $82,620 per year. On February 4, 2016, the Company extended its facility lease to extend the term of the lease until August 31, 2019 at a monthly base rent of $7,306 plus a pro rata share of landlord’s operating expenses. Effective September 1, 2019, the Company entered into a second amendment to extend the lease through August 31, 2024 with base rent beginning at $87,674 per year and escalating to $98,678 per year plus a pro rata share of the landlord’s operating expenses. On September 1, 2019, the lease commencement date, the Company estimated the lease liability and the right of use assets at present value using the Company’s estimated incremental borrowing rate of 8% and determined their initial present values, at inception, of $383,351. In determining the length of the lease term to its long-term lease, the Company determined there was not an option to extend the lease. In determining the length of the lease term for this long-term lease, the Company determined there was not an option to extend the lease. At lease commencement date, the Company estimated the lease liability and the right of use assets at present value using the Company’s estimated incremental borrowing rate of 8% and determined the initial present value, at inception, of $274,180. On January 1, 2019, upon adoption of ASC Topic 842, the Company recorded right to use assets of $56,734 and lease liability of $56,734. On October 24, 2019, the Company entered into an Assignment and Assumption of Lease by and between the Company, American Cell Technology, LLC, and Sawgrass Business Plaza, LLC. Subsequently, the Company relocated to a new location within the same city and entered into a month-to-month lease. Accordingly, the right of use assets and lease liabilities were eliminated. During the three and nine months ended September 30, 2020 and 2019, lease expense was comprised of the following: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2020 2019 2020 2019 Operating lease expense $ 1,689 $ 34,560 $ 3,891 $ 105,200 Variable lease expense - - - 685 Total lease expense $ 1,689 $ 34,560 $ 3,891 $ 105,885

ACCRUED EXPENSES

ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 7 ACCRUED EXPENSES Accrued expenses consisted of the following as of September 30, 2020 and December 31, 2019: September 30, December 31, Interest and fees payable to the Guarantors of the Company’s loan agreement with Seaside Bank $ 522,746 $ 456,190 Accrued interest payable 777,937 580,204 Vendor accruals and other 79,138 79,132 Accrued expenses and other current liabilities $ 1,379,821 $ 1,115,526 During the nine months ended September 30, 2020, the Company issued 1,445,647 shares of its common stock, having a fair value of $11,565, in lieu of payment in cash of accrued and unpaid interest of $9,145, resulting in a loss on settlement of $2,420.

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended
	Sep. 30, 2020
Disclosure Text Block [Abstract]
Debt and Capital Leases Disclosures [Text Block]	NOTE 8 NOTES PAYABLE Notes payable were comprised of the following as of September 30, 2020 and December 31, 2019: September 30, December 31, Seaside Bank note payable $ 980,000 $ 980,000 Hunton & Williams note payable 387,500 391,000 Weider note payable 453,493 482,939 Mallard note payable 243,250 250,000 EIDL note payable 150,000 - Total notes payable 2,214,243 2,103,939 Less unamortized debt discount (43,592 ) (50,448 ) Total notes payable net of unamortized debt discount 2,170,651 2,053,491 Less current portion (1,400,910 ) (1,297,477 ) Long-term portion $ 769,741 $ 756,014 Seaside Bank On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by certain stockholders of the Company. The Company renewed the loan with Seaside National Bank and Trust during the first quarter of 2018 to extend the maturity date to May 18, 2020. The Company renewed the loan with Seaside National Bank and Trust during the first quarter of 2020 to extend the maturity date to May 18, 2022. Hunton & Williams At December 31, 2016, the Company has two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822, are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar Biotech Group, LLC (or successor) Loan is paid off. On August 31, 2017, the Company and the noteholder entered into a Note Forbearance, Modification and Repayment Agreement (“Agreement”). The two notes, $61,150 and $323,822, were payable in one balloon payment upon the date of a written demand and upon certain triggering events occurring. The sum of unpaid principal and accumulated interest for both notes as of August 31, 2017 of $747,680 and an account payable of $40,596 result in an aggregate balance due of $788,276. The noteholder agreed to accept full payment of their obligation over a four (4) year period in 48 monthly installments on an adjusted debt obligation in aggregate of $624,000 (reducing the outstanding balance), with such payments staggered in amounts such that the Company will pay $10,000 monthly the first year, $12,000 monthly the second year, $14,000 monthly the third year, and $16,000 monthly the final year. In addition, the noteholder agreed to suspend accrual interest on the notes commencing September 1, 2017. The Agreement remains in full force and effect provided the Company continues to make the monthly payments, there is no event of default as defined in the notes and an agreement to a subordination agreement by Northstar Biotech Group, LLC, which has been provided. In May 2019, the Company did not make the required scheduled payment. In September 2010, the noteholder agreed to waive their default rights under the agreement provided a minimum of $5,000 was paid by the end of 2019 and to reduce the required monthly payment to $500 per month commencing in January 2020. The Company satisfied the $5,000 payment requirement by the end of 2019 and commenced making the required $500 monthly payments in January 2020. The Company imputed an interest rate of 5% and discounted the note accordingly. The imputed debt discount of $69,700 was amortized to interest expense using the effective interest method. For the three and nine months ended September 30, 2020, the Company amortized $0 debt discount; and $24,205 and $34,945 for the three and nine months ended September 30, 2019, respectively, of debt discount to interest expense. At September 30, 2020, the Company was in default and was renegotiating the payment structure. Thus, the remaining unamortized debt discount was charged to interest expense at September 30, 2020. As of September 30, 2020 and December 31, 2019, the remaining carrying value of the note was $387,500 and $391,000, respectively. Weider The Company, as one of the parties entered into a Settlement Agreement and General Release (the “Agreement”) dated June 3, 2019 related to certain medical procedures. Without admitting any liability, and as part of that Agreement, the Company agreed to provide a five-year 5.25% unsecured promissory note, dated June 15, 2019, in the principal amount of $500,000, payable in monthly increments of $5,000 per month, with a final balloon payment due on June 15, 2024. As of September 30, 2020 and December 31, 2019, the remaining carrying value of the note was $453,493 and $482,939, respectively. Mallard The Company, as one of the parties entered into a Settlement Agreement and General Release (the “Agreement”) dated December 6, 2019 related to certain medical procedures. Without admitting any liability, and as part of that Agreement, the Company agreed to provide a five-year non-interest bearing unsecured promissory note, dated December 6, 2019, in the principal amount of $250,000, payable in monthly increments of $750 per month, with a final balloon payment of $205,000 due on January 1, 2025. The Company imputed an interest rate of 5% and discounted the note accordingly. The imputed debt discount of $51,063 is being amortized to interest expense using the effective interest method. For the three and nine months ended September 30, 2020, the Company amortized $2,328 and $6,857, respectively, of debt discount to interest expense. As of September 30, 2020 and December 31, 2019, the remaining carrying value of the note was $199,658 and $199,551, net of debt discount of $43,592 and $50,448, respectively. Economic Injury Disaster Loan (EIDL) On June 20, 2020, the Company executed the standard loan documents for an EIDL from the U.S. Small Business Administration in light of the impact of the COVID-19 pandemic on our business. Pursuant to that certain Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL received was $150,000, with proceeds to be used for working capital purposes. Interest accrues at the rate of 3.75% per annum. Installment payments, including principal and interest, are due monthly beginning June 20, 2021 (twelve months from the date of the SBA Loan Agreement) in the amount of $731. The balance of principal and interest is payable thirty years from the date of the SBA Loan Agreement. As of September 30, 2020, the remaining carrying value of the note was $150,000. At September 30, 2020, accrued interest on the note was $1,572, and is included in accrued expenses on the accompanying balance sheet.

PROMISSORY NOTE PAYABLE

PROMISSORY NOTE PAYABLE	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 9 PROMISSORY NOTE PAYABLE On June 1, 2015, the Company issued an amended and restated promissory note of $1,697,762 in settlement of the $1,500,000 outstanding subordinated debt, related accrued interest of $373,469 and accumulated and unpaid guarantor fees of $624,737. The note is unsecured and non-interest bearing and requires four semi-annual payments of $75,000 beginning on December 31, 2015 with the remaining unpaid balance due June 1, 2020. On June 1, 2020, the Company defaulted on the promissory note. Upon default, the note became due in full and the Company began accruing interest at the default interest rate of 18%. The Company imputed an interest rate of 5% and discounted the promissory note accordingly. The imputed debt discount of $368,615 was amortized to interest expense using the effective interest method. For the three and nine months ended September 30, 2020, the Company amortized $0 and $29,295, respectively of debt discount; and $17,616 and $52,273 for the three and nine months ended September 30, 2019, respectively, of debt discount to interest expense. As of September 30, 2020 and December 31, 2019, the remaining carrying value of the note was $1,397,762 and $1,368,467, net of debt discount of $0 and $29,296, respectively.

CONVERTIBLE NOTE PAYABLE

CONVERTIBLE NOTE PAYABLE	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Short-term Debt [Text Block]	NOTE 10 CONVERTIBLE NOTE PAYABLE On February 5, 2020, the Company issued an unsecured convertible promissory note in the principal amount of $35,000 that matures on February 5, 2021 and bears interest at a rate of 5% per annum. The investor has the right to convert the outstanding balance of the note at any time into shares of common stock of the Company at a conversion price equal to a thirty percent (30%) discount of the average closing price of the Company’s common stock on the OTC Markets electronic exchange for the prior thirty (30) trading days prior to conversion, subject to adjustment. Upon the occurrence of an event of default, the investor may accelerate the note pursuant to which the outstanding balance will become, at the noteholder’s election, immediately due and payable. As a result of the beneficial conversion feature of the note, debt discount of $15,000 was recognized with a corresponding increase in additional paid-in capital. The debt discount is being amortized to interest expense using the effective interest method. For the three and nine months ended September 30, 2020, the Company amortized $3,777 and $8,779, respectively, of debt discount to interest expense. As of September 30, 2020, the remaining carrying value of the note was $28,779, net of debt discount of $6,221. At September 30, 2020, accrued interest on the note was $1,141, and is included in accrued expenses on the accompanying balance sheet. On September 8, 2020, the Company issued an unsecured convertible promissory note in the principal amount of $10,000 that is due on demand and bears interest at a rate of 5% per annum. The investor has the right to convert the outstanding balance of the note at any time into shares of common stock of the Company at a conversion price of $0.0467. Upon the occurrence of an event of default, the remaining principal and accrued interest become immediately due and payable, with interest accruing at 18% per annum on any unpaid amounts. As of September 30, 2020, the remaining carrying value of the note was $10,000. At September 30, 2020, accrued interest on the note was $30, and is included in accrued expenses on the accompanying balance sheet.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 11 RELATED PARTY TRANSACTIONS Advances Related Parties As of September 30, 2020 and December 31, 2019, the Company’s officers and directors have provided advances that are unsecured, non-interest bearing and due on demand. During the nine months ended September 30, 2020 and 2019, the Company received aggregate proceeds from advances of $285,296 and $140,000, respectively. As of September 30, 2020 and December 31, 2019, the Company owed $797,040 and $511,744, respectively, for advances. Notes Payable Related Parties Northstar Biotechnology Group, LLC On February 29, 2012, a promissory note issued to BlueCrest Master Fund Limited (“BlueCrest”) was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company at the time, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267 (the “Note”). On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May 1, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement. The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock. On September 21, 2012, the Company issued 5,000 common stock purchase warrants to Northstar that was treated as additional interest expense upon issuance. On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 shares of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights. In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing, and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated. Effective October 1, 2012, the interest rate was 12.85% per annum. The parties agreed, as of February 28, 2013, to reduce the interest rate to 7% per annum. In connection with the consideration paid, Northstar waived, from the effective date through the earlier of termination or expiration of the agreement, satisfaction of the obligations as described in the forbearance agreement. In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued, which was subsequently increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. In addition, the Company was obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six-month anniversary of the effective date (October 1, 2012). In lieu of the initial two payments in preferred stock, the parties agreed to modify the voting rights of the subsequently cancelled Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stockholders to 25 votes per share on matters to be voted on by the common stockholders and all prior and subsequent payments of interest will be in common stock. The Company is required to issue additional shares of its common stock (as amended), in lieu of cash, each six-month anniversary of the effective date for any accrued and unpaid interest. On September 30, 2013, the Company issued 8,772 shares of its common stock as payment of $100,000 towards principal. On December 24, 2013, the Company issued 3,916 shares of its common stock as payment of accrued interest through June 30, 2013 of $85,447. On April 2, 2014, the Company issued 275 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2014 per the forbearance agreement. On September 17, 2014, the limited waiver and forbearance agreement entered into on October 1, 2012 to provide that the perpetual license on products as described for resale, relicensing and commercialization outside the United States was amended as such on the condition that Northstar provide certain financing, which financing the Company, in its sole discretion, could decline and retain the license. On October 3, 2014, the Company issued 515 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2014 per the forbearance agreement. On April 3, 2015, the Company issued 1,363 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2015 per the forbearance agreement. On October 2, 2015, the Company issued 4,156 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2015 per the forbearance agreement. On October 7, 2015, the Company issued 34,522 shares of its common stock in settlement of $100,000 principal payment towards the outstanding debt. On April 7, 2016, the Company issued 57,778 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due April 1, 2016 per the forbearance agreement. On October 6, 2016, the Company issued 848,490 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2016 per the forbearance agreement. On March 1, 2017, Northstar and the Company entered into a settlement agreement (“Settlement Agreement “) related to then pending litigation. Pursuant to the terms and conditions of the Settlement Agreement, Northstar converted its outstanding Series A Convertible preferred stock, into twenty million (20,000,000) shares of common stock according to the original conversion terms. In addition, and separate and apart from the conversion, Northstar received eleven million (11,000,000) shares of the Company’s common stock. Northstar will receive ten percent (10%) of all Company international sales (based on a gross sales basis). There was no effect of the 10% obligation as there were no international sales in 2017 or through 2019. Furthermore, a Northstar designee, Greg Knutson, was appointed as a member of the Board of Directors of the Company and two Company directors, Michael Tomas and Kristin Comella, each exercised their prior Northstar options to each receive a five percent (5%) member interest in Northstar. The parties agreed to a mutual release and Northstar agreed to terminate any UCC lien on the Company assets previously filed for the benefit of Northstar. On March 9, 2017 and April 1, 2017, the Company issued 30,000,000 and 1,000,000 shares of its common stock, respectively, as described above. In connection with the settlement, the Company recorded a loss on litigation settlement of $316,800. On April 1, 2017, the Company issued 286,315 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,703. On October 2, 2017, the Company issued 559,187 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705. On October 19, 2018, the Company issued 164,523 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $9,195. On April 19, 2019, the Company issued 379,141 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $9,145. On October 1, 2019, the Company issued 1,692,353 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $9,195. On April 1, 2020, the Company issued 1,445,647 shares of its common stock, having a fair value of $11,565, in lieu of payment in cash of accrued and unpaid interest of $9,145, resulting in a loss on settlement of $2,420. As of September 30, 2020 and December 31, 2019, the remaining carrying value of the note was $262,000. At September 30, 2020 and December 31, 2019, accrued interest on the note was $13,323 and $8,700, respectively, and is included in accrued expenses on the accompanying balance sheet. Notes Payable - Mr. Tomas, President and Chief Executive Officer On August 7, 2017, the Company issued a $500,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due one year from date of issuance. During the nine months ended September 30, 2020 and 2019, the Company paid principal of $0 and $321,607, respectively, of this note. As of September 30, 2020 and December 31, 2019, the remaining carrying value of the note was $161,786. On May 7, 2018, the Company issued a $500,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due six months from date of issuance. As of September 30, 2020 and December 31, 2019, the remaining carrying value of the note was $500,000. On July 1, 2019, the Company issued a $500,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due November 7, 2019. As of September 30, 2020 and December 31, 2019, the remaining carrying value of the note was $500,000. On December 31, 2019, the Company issued a $178,077 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of September 30, 2020 and December 31, 2019, the remaining carrying value of the note was $178,077. On March 31, 2020, the Company issued a $187,500 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of September 30, 2020, the remaining carrying value of the note was $187,500. On June 30, 2020, the Company issued a $187,500 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of September 30, 2020, the remaining carrying value of the note was $187,500. On July 1, 2020, the Company issued a $500,000 promissory note as payment of an annual bonus awarded. The promissory note bears interest of 5% per annum and is due on demand. As of September 30, 2020, the remaining carrying value of the note was $500,000. On September 30, 2020, the Company issued a $100,962 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of September 30, 2020, the remaining carrying value of the note was $100,962. At September 30, 2020 and December 31, 2019, accrued interest on the notes was $453,282 and $389,695, respectively, and is included in accrued expenses on the accompanying balance sheet. Notes Payable - Dr. Comella, former Chief Science Officer as of September 30, 2020. On September 6, 2016, the Company issued a $300,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due upon demand. During the nine months ended September 30, 2019, the Company received back $107,868 of principal amounts previously paid for this note. As of September 30, 2020 and December 31, 2019, the remaining carrying value of the note was $255,579. On August 7, 2017, the Company issued a $300,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due one year from date of issuance. As of September 30, 2020 and December 31, 2019, the remaining carrying value of the note was $300,000. On May 7, 2018, the Company issued a $300,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due six months from date of issuance. As of September 30, 2020 and December 31, 2019, the remaining carrying value of the note was $300,000. On July 1, 2019, the Company issued a $300,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due November 7, 2019. As of September 30, 2020 and December 31, 2019, the remaining carrying value of the note was $300,000. At September 30, 2020 and December 31, 2019, accrued interest on the notes was $194,081 and $150,708, respectively, and is included in accrued expenses on the accompanying balance sheet. Dr. Comella is no longer a member of the Board of Directors after September 1, 2019. September 30, December 31, Northstar $ 262,000 $ 262,000 Note payable, Mr. Tomas 161,786 161,786 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 178,077 178,077 Note payable, Mr. Tomas 187,500 - Note payable, Mr. Tomas 187,500 - Note payable, Mr. Tomas 500,000 - Note payable, Mr. Tomas 100,962 - Note payable, Dr. Comella* 255,579 255,579 Note payable, Dr. Comella* 300,000 300,000 Note payable, Dr. Comella* 300,000 300,000 Note payable, Dr. Comella* 300,000 300,000 Total officer and director notes $ 3,733,404 $ 2,757,442 * Dr. Comella is no longer a member of the Board of Directors effective September 1, 2019. Other Transactions Related Parties Transactions with GACP On March 3, 2017, the Company entered into an asset sale and lease agreement (sale/leaseback transaction, the “Asset Sale and Lease Agreement”) with General American Capital Partners (GACP), whereby the Company sold certain lab, medical and other equipment relating to the cell banking business for $400,000 and leased back the sold equipment over a three-year term. The Company determined that the transaction was a capitalized lease and accordingly recorded the leased assets and liabilities based on the estimated present value of the minimum lease payments. In connection with the Asset Sale and Lease Agreement, the Company is obligated to accrue 10% of cell-banking revenue as for marketing, offset by any incurred costs of the Company. At September 30, 2020 and December 31, 2019, the outstanding accrued marketing obligation is $0. On March 3, 2017, the Company also entered into a customer purchase agreement with GACP whereby the Company received a deposit $50,000 (included in long-term liabilities at December 31, 2018) in exchange for the sale of the first 5,000 future customers of the cell-banking business after the effective date of the agreement; GACP also had the right to purchase additional customers at a price of $20 per customer. There is no reduction in the selling price should the new customers be fewer than 5,000. The effective date of the sale is upon the expiry or early termination of the aforementioned Asset Sale and Lease Agreement. March 3, 2017, the Company also entered into an asset purchase agreement of intellectual property with GACP whereby the Company received a deposit of $50,000 (included in long-term liabilities at December 31, 2018) for the sale of all of the Company’s worldwide rights, title or interest in certain intellectual and other property (as defined) associated with the cell-banking business. The effective date of the sale is upon the expiry or early termination of the aforementioned Asset Sale and Lease Agreement. Effective May 9, 2018, pursuant to an Amendment to the Asset Sale and Lease Agreement, GACP suspended their obligation to open additional clinics (tolling such obligation to a mutually agreeable date in the future) and it has suspended the monthly aggregate number of stem cell kits set forth for purchase in a given month arising from such clinics. As a consequence of the Court Order dated June 4, 2019 (see Note 13 “Government Claim”), the Company resolved to divest itself of certain equipment and other assets (the “Equipment Assets”) used in connection with the Company’s human tissue banking business, but consistent however with the requirements of the Court Order, and to adjust the business plan and operations to accommodate this potential divesture. To facilitate the above, the Company entered into the following agreements: ● Termination and Release Agreement by and between GACP, the Company, and Michael Tomas and Kristin Comella dated September 24, 2019 (terminating the Non-Competition and Non-Solicitation Agreement between U.S. Stem Cell, Inc. and GACP Stem Cell Bank LLC., dated March 3, 2017). ● Letter Agreement on Stem Cell Processing and Storage by and between the Company and American Cell Technology, LLC Effective October 9, 2019, the Company terminated the Asset Sale and Lease Agreement by and between the Company and GACP. Accordingly, the long-term deposit liabilities were written off, resulting in a gain on debt settlement of $100,000. In addition, the right of use assets and lease liabilities were also written off.

FAIR VALUE MEASUREMENT

FAIR VALUE MEASUREMENT	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 12 FAIR VALUE MEASUREMENT The Company adopted the provisions of ASC 825-10. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: ● Level 1 – Quoted prices in active markets for identical assets or liabilities. ● Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon Level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. As of September 30, 2020 and December 31, 2019, the Company did not have any items that would be classified as level 1, 2 or 3 disclosures. As of September 30, 2020 and December 31, 2019, the Company did not have any derivative instruments that were designated as hedges.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 13 COMMITMENTS AND CONTINGENCIES Royalty Agreement / Middle East On November 9, 2016, the Company entered into an Intellectual Property License Agreement whereby the Company granted High Rise Group Company the exclusive right to the Company’s intellectual property (as defined) for the licensed use and development in Kuwait and other GCC/Middle East countries for 25 years in exchange for a payment of $75,000 and a 5% royalty generated under the agreement. The licensing agreement is recorded as deferred revenue and amortized over the term of the agreement. The carrying balance as of September 30, 2020 and December 31, 2019 was $63,250 and $65,500, respectively. The intent is for U.S. Stem Cell Middle East to offer regenerative treatment options to patients, based on U.S. Stem Cell, Inc. products and technologies like MyoCell™. To date, the first clinic in Kuwait City has been completed but has not begun operations as High Rising Group has not yet been able to secure regulatory approvals to operate. Litigation On December 12, 2017, a product liability lawsuit was filed in Broward County, specifically Jeannine Mallard v. U.S. Stem Cell, Inc., US Stem Cell Clinics LLC., Regenestem, LLC., Regenestem Network, LLC., and Kristin C. Comella. The Company will continue to defend it vigorously. On December 6, 2019, the Company was one of the parties to a Settlement Agreement and General Release (the “Agreement”) related to certain medical procedures. Without admitting any liability, and as part of that Agreement, the Company agreed to provide a five-year non-interest bearing unsecured promissory note, dated December 6, 2019, in the principal amount of $250,000, payable in monthly increments of $750 per month, with a final balloon payment of $205,000 due on January 1, 2025 (see Note 8, “Mallard”). On September 17, 2015, a product liability lawsuit was filed in Broward County, specifically Patsy Bade v. Bioheart, Inc. US Stem Cell Clinics LLC, Alejandro Perez, ARNP, and Shareen Greenbaum, M.D., and on November 30, 2015, a product liability lawsuit was filed in Broward County, specifically Elizabeth Noble v. Bioheart, Inc. US Stem Cell Clinics LLC, Alejandro Perez, ARNP, and Shareen Greenbaum, M.D. During the year ended December 31, 2016, both matters settled by the Company’s insurance policy with no additional cost to the Company, except for the obligation to pay the insurance company deductible of $100,000, of which $11,000 was paid in fiscal 2017. The remaining amount due under this settlement is $28,850 and $30,050 as of September 30, 2020 and December 31, 2019, respectively, and is included in accounts payable. On June 3, 2019, the Company was one of the parties to a Settlement Agreement and General Release (the “Agreement”) related to certain medical procedures. Without admitting any liability, and as part of that Agreement, the Company agreed to provide a five-year 5.25% Promissory Note, dated June 15, 2019, in the principal amount of Five Hundred Thousand Dollars ($500,000), payable in monthly increments of Five Thousand ($5,000) per month (see Note 8, “Weider”). The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity. There was no outstanding litigation as of September 30, 2020 other than that described above. Government Claim On May 9, 2018, the U.S. Department of Justice filed an injunctive action, specifically United States of America v. U.S. Stem Clinic, LLC, U.S. Stem Cell, Inc., Kristin C. Comella, and Theodore Gradel. The Complaint alleges, among other matters that the defendants manufacture “stromal vascular fraction” (SVF) products from patient adipose (fat) tissue, which the companies then market as stem cell-based treatments, and which U.S. Stem Cell Clinic, LLC administers to patients, without first obtaining what the government alleges are necessary FDA approvals. Although Theodore Gradel was initially listed as a defendant, he subsequently entered into a consent agreement and is no longer party to this case. The U.S. and the defendants filed cross motions for summary judgment, each asking for a ruling in its favor. On June 3, 2019, the Court entered an order granting Summary Judgment for the government and denying the defendants’ motion for summary judgment. The order focused on the defendants’ actions in providing and marketing SVF therapy. In an order dated June 4, 2019, the Court granted the defendants’ request to allow it the opportunity to work out the language of the form of injunction with the government, and if unsuccessful, to provide a status report to the Court by June 14, 2019, outlining areas of disagreement. The Court further ordered that the defendants (U.S. Stem Clinic, LLC, U.S. Stem Cell, Inc., and Kristin C. Comella) ‘not sell, provide or otherwise engage in any SVF therapy or any other activities to be regulated by the FDA as explained in the Court’s Order on the Parties’ Motions for Summary Judgment.” On June 25, 2019, the Court entered an Order of Permanent Injunction, generally enjoining the defendants with respect to the SVF Product and requiring other actions. The Company filed an appeal on August 23, 2019 and attended oral argument on January 13, 2021. On June 2, 2021, the Eleventh Circuit Court ruled to affirm lower courts’ judgement. The Company did not challenge the district court’s judgment upon any other ground. The Company, in divesting certain equipment and other assets and assigning its lease, has and will continue to experience a decrease in revenues as the Company both maintains the remainder of the business and transitions into similar or unrelated business opportunities as determined by management. However, management is not able to predict the duration, scope, results, or consequences of the summary judgment and any transition of the business plan. Since the Court’s issuance of the Order of Permanent Injunction, the Company has received demand letters for compensation from persons who store their SVF Product and/or other tissue product with the tissue bank (several of the persons have requested refunds of the monies paid to the tissue bank and one person has requested a full refund of monies paid to an altogether separate company due to her not receiving the full amount of treatments she requested; such requests for compensation, to date, have not been material) and requests that the Company preserve cells in the Company’s possession. The Company sought guidance from the Court, which entered an order generally staying the requirement to destroy any SVF Product, pending a decision on the Company’s appeal.

STOCKHOLDERS' DEFICIT

STOCKHOLDERS' DEFICIT	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 14 STOCKHOLDERS DEFICIT Common Stock During the nine months ended September 30, 2020, the Company issued an aggregate of 6,532,248 shares of its common stock, having a fair value of $32,803, in settlement of outstanding accounts payable. In connection with the issuances, the Company incurred a $2,697 net gain on settlement. During the nine months ended September 30, 2020, the Company issued 1,445,647 shares of its common stock, having a fair value of $11,565, in lieu of payment in cash of accrued and unpaid interest of $9,145, resulting in a loss on settlement of $2,420. During the nine months ended September 30, 2020, the Company issued an aggregate of 4,000,000 shares of its common stock, having a fair value of $16,000, for services. Stock Options On April 1, 2013, the Board of Directors approved, subject to subsequently received stockholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan” (replacing the 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan). The 2013 Omnibus Plan initially reserved up to fifty thousand (50,000) shares of common stock for issuance. On August 4, 2014, the Board of Directors approved to set the reserve to one hundred thousand (100,000) shares of common stock for issuance and to close the 1999 Officers and Employees Stock Option Plan. On February 2, 2015, at the annual meeting of stockholders, the 2013 Omnibus Equity Compensation Plan was approved. On November 2, 2015, the Company increased the shares reserved under the 2013 Omnibus Plan to five hundred million (500,000,000) shares of common stock for issuance. Effective September 16, 2016, the Company approved an additional twenty five million (25,000,000) shares of common stock to the reserve; effective April 21, 2017, the Company approved an additional twenty five million (25,000,000) shares of common stock to the reserve; effective August 7, 2017, the Company approved an additional thirty million (30,000,000) shares of common stock to the reserve; and effective May 7, 2018, the Company approved an addition of one hundred million (100,000,000) shares of common stock to reserve. A summary of the stock option activity for the nine months ended September 30, 2020 is as follows: Weighted Weighted Average Average Number of Exercise Remaining Life Intrinsic Options Price In Years Value Outstanding, December 31, 2019 111,120,474 $ 0.0247 8.3 $ - Granted - Exercised - Forfeited/Expired (560 ) $ 0.1540 Outstanding, September 30, 2020 111,119,914 $ 0.0247 7.8 $ - Exercisable, September 30, 2020 75,737,414 $ 0.0255 7.2 $ - Options Outstanding Options Exercisable Weighted Weighted Weighted Outstanding Average Average Exercisable Average Exercise Number of Exercise Remaining Life Number of Exercise Price Options Price In Years Options Price $0.004 to $0.010 41,900,000 $ 0.0051 8.3 21,650,000 $ 0.0049 $0.011 to $0.020 16,300,000 $ 0.0196 6.0 16,300,000 $ 0.0196 $0.021 to $0.030 9,710,000 $ 0.0253 8.1 8,605,000 $ 0.0252 $0.0363 22,735,000 $ 0.0363 6.9 18,707,500 $ 0.0363 $0.0536 20,000,000 $ 0.0536 7.6 10,000,000 $ 0.0536 $0.1540 474,914 $ 0.1540 5.0 474,914 $ 0.1540 111,119,914 $ 0.0247 7.5 75,737,414 $ 0.0255 The aggregate intrinsic value of outstanding stock options was $0, based on options with an exercise price less than the Company’s stock price of $0.0043 as of September 30, 2020, which would have been received by the option holders had those option holders exercised their options as of that date. The fair value of all options that vested during the nine months ended September 30, 2020 and 2019 was $525,336 and $512,882, respectively. As of September 30, 2020, the Company had $890,216 of total unrecognized compensation cost related to non-vested awards granted under the 2013 Omnibus Plan, which the Company expects to recognize over a weighted average period of 0.92 years. Warrants A summary of the warrant activity for the nine months ended September 30, 2020 is as follows: Weighted Weighted Average Average Remaining Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2019 1,110,468 $ 12.8400 8.2 $ - Granted - Exercised - Expired - Outstanding, September 30, 2020 1,110,468 $ 12.84 7.4 $ - Exercisable, September 30, 2020 1,108,923 $ 2.14 7.4 $ - Warrants Outstanding Warrants Exercisable Weighted Weighted Weighted Outstanding Average Average Exercisable Average Exercise Number of Exercise Remaining Life Number of Exercise Price Warrants Price In Years Warants Price $0.03 to $20.00 1,086,536 $ 1.27 7.5 1,086,536 $ 1.27 $20.01 to $30.00 19,543 $ 25.06 3.4 19,543 $ 25.06 $40.01 to $50.00 2,253 $ 48.83 2.0 2,253 $ 48.83 $50.01 to $60.00 543 $ 60.00 0.8 543 $ 60.00 >$60.00 1,593 $ 7,690.00 6.1 48 $ 7,690.00 1,110,468 $ 12.84 7.4 1,108,923 $ 2.14 The aggregate intrinsic value of the issued and exercisable warrants of $0 represents the total pretax intrinsic value, based on warrants with an exercise price less than the Company’s stock price of $0.0043 as of September 30, 2020, which would have been received by the warrant holders had those warrants holders exercised their warrants as of that date.

CONCENTRATIONS

CONCENTRATIONS	9 Months Ended
	Sep. 30, 2020
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	NOTE 15 CONCENTRATIONS Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. Concentrations of Revenues For the three and nine months ended September 30, 2020 and 2019, the following customers accounted for more than 10% of the Company’s net revenues: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2020 2019 2020 2019 Customer 1 24 % - 15 % - Customer 2 15 % - - - Customer 3 14 % - - - Customer 4 - - 13 % - Customer 5 - 27 % - 12 % Customer 6 - 22 % - - Totals 53 % 49 % 28 % 12 % Customer 5 is U.S. Stem Cell Clinic, LLC, a related party, a partly owned investment in which the Company holds a 49.9% member interest. Concentrations of Accounts Receivable As of September 30, 2020 and December 31, 2019, the following customers represented more than 10% of the Company’s accounts receivable: September 30, December 31, Customer 1 83 % 47 % Customer 2 - 47 % Totals 83 % 94 % Customer 1 is U.S. Stem Cell Clinic, LLC, a related party, a partly owned investment in which the Company holds a 49.9% member interest.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 16 SUBSEQUENT EVENTS In March 2021, the Company divested its entire interest in U.S. Stem Cell Clinic, LLC.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable, accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.
Equity Method Investments [Policy Text Block]	Investments The Company follows Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 49.9% member interest ownerships of U.S. Stem Cell Clinic, LLC and Regenerative Wellness Clinic, LLC, respectively, and its 49% member interest ownership of U.S. Stem Cell Clinic of the Villages utilizing the equity method of accounting (See Note 5).
Revenue [Policy Text Block]	Revenue Recognition Effective January 1, 2018, the Company recognizes revenue in accordance with Accounting Standards Codification 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client. The Company’s primary sources of revenue are from the sale of test kits and equipment, training services, patient treatments, laboratory services and cell banking. Revenues for kits and equipment sold are not recorded until kits and equipment are received by the customer. Revenues from in-person trainings are recognized when the training occurs and revenues from on demand online trainings are recognized when the customer purchases the rights to the training course. Any cash received as a deposit for trainings are recorded by the Company as a liability. Patient treatments and laboratory services revenue are recognized when those services have been completed or satisfied. Revenues for cell banking are accounted for as multiple performance obligations as described in ASC 606 and addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. Because the Company sells its services separately, on more than a limited basis and at a price within a narrow range, the Company was able to allocate revenue based on stand-alone pricing. The multiple performance obligations include stem cell banking, dose retrieval and yearly storage fees. Revenues for stem cell banking and dose retrieval is recognized at the point of service and revenues for the yearly storage fees is recognized over the term of the banking contract, which is typically one year with annual renewals. At September 30, 2020 and December 31, 2019, the Company had deferred revenues of $83,250 and $86,300, respectively, which includes $63,250 and $65,500, respectively, for the Intellectual Property Licensing Agreement.
Research and Development Expense, Policy [Policy Text Block]	Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $0 for the three and nine months ended September 30, 2020, respectively; and $0 and $263 for the three and nine months ended September 30, 2019, respectively.
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation Stock-based compensation expense is measured at the grant date fair value of the award and is expensed over the requisite service period. For stock-based awards to employees, non-employees and directors, the Company calculates the fair value of the award on the date of grant using the Black-Scholes option pricing model. Determining the fair value of stock-based awards at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based awards represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted income (loss) per share as of September 30, 2020 and 2019 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2020 2019 Options 111,119,914 121,038,655 Warrants 1,110,468 1,112,251 Convertible note 11,260,433 - Total potentially dilutive shares 123,490,815 122,150,906
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements FASB Accounting Standards Updates (“ASU”) 2017-04 (Topic 350), “Intangibles – Goodwill and Others” – Issued in January 2017, ASU 2017-04 simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. This guidance was effective for the Company in the first fiscal quarter of 2020. The adoption of this standard did not have a material impact on the Company’s financial statements and related disclosures. In February 2016, the FASB established ASC Topic 842, Leases (Topic 842), by issuing ASU No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company adopted the new standard on January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. The new standard had a material effect on the Company’s financial statements. The most significant effects of adoption relate to (1) the recognition of new ROU assets and lease liabilities on its balance sheet for real estate operating leases; and (2) providing significant new disclosures about its leasing activities. Upon adoption, the Company recognized additional operating lease liabilities, net of deferred rent, of approximately $57,000 based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases. The Company also recognized corresponding ROU assets of approximately $57,000. On October 24, 2019, the Company entered into an Assignment and Assumption of Lease by and between the Company, American Cell Technology, LLC, and Sawgrass Business Plaza, LLC. Subsequently, the Company relocated to a new location within the same city and entered into a month-to-month lease. Accordingly, the right of use assets and lease liabilities were eliminated. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. Beginning in 2019, the Company changed to its disclosed lease recognition policies and practices, as well as to other related financial statement disclosures due to the adoption of this standard. FASB ASU No. 2018-07 (Topic 718), “Compensation – Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting” – Issued in June 2018, ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606. The Company adopted the new standard on January 1, 2019. The adoption of this guidance did not have a material impact on the Company’s financial condition or results of operations. In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on accounting for convertible debt instruments by removing the separation models for: (1) convertible debt with a cash conversion feature; and (2) convertible instruments with a beneficial conversion feature. As a result, the Company will not separately present in equity an embedded conversion feature in such debt. Instead, we will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. We expect the elimination of these models will reduce reported interest expense and increase reported net income for the Company’s convertible instruments falling under the scope of those models before the adoption of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will be no longer available. The provisions of ASU 2020-06 are applicable for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements. In August 2018, the FASB issued Accounting Standards Update (“ASU”) 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”). ASU 2018-13 removes certain disclosure requirements, including the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels, and the valuation processes for Level 3 fair value measurements. ASU 2018-13 also adds disclosure requirements, including changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements, and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. The amendments on changes in unrealized gains and losses, and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. This guidance was effective for the Company in the first fiscal quarter of 2020. The adoption of this standard did not have a material impact on the Company’s financial statements and related disclosures. There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from these estimates.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts. Credit is extended to customers based on an evaluation of their financial condition, industry reputation, and other judgmental factors considered by the Company’s management. The Company generally does not require collateral or other security interest to support accounts receivable. Based on trends and specific factors, the customer’s credit terms may be modified, including required payment upon delivery. The Company performs regular on-going credit evaluations of its customers as deemed relevant. As events, trends, and circumstance warrant, the Company’s management estimates the amounts that are more likely than not to be uncollectible. These amounts are recognized as bad debt expense and are reflected within selling, general, administrative and other expenses on the Company’s accompanying statement of operations. Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of September 30, 2020 and December 31, 2019, the allowance for doubtful accounts was $13,203.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2020 2019 Options 111,119,914 121,038,655 Warrants 1,110,468 1,112,251 Convertible note 11,260,433 - Total potentially dilutive shares 123,490,815 122,150,906

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of September 30, 2020 and December 31, 2019 is summarized as follows: September 30, December 31, Furniture, fixtures and equipment $ 5,598 $ 5,598 Computer equipment 1,809 1,809 Property and equipment, cost 7,407 7,407 Less: accumulated depreciation and amortization (7,407 ) (7,407 ) Property and equipment, net $ - $ -

RIGHT TO USE ASSETS AND LEASE_2

RIGHT TO USE ASSETS AND LEASE LIABILITY (Tables)	9 Months Ended
	Sep. 30, 2020
Disclosure Text Block [Abstract]
Lease, Cost [Table Text Block]	During the three and nine months ended September 30, 2020 and 2019, lease expense was comprised of the following: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2020 2019 2020 2019 Operating lease expense $ 1,689 $ 34,560 $ 3,891 $ 105,200 Variable lease expense - - - 685 Total lease expense $ 1,689 $ 34,560 $ 3,891 $ 105,885

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consisted of the following as of September 30, 2020 and December 31, 2019: September 30, December 31, Interest and fees payable to the Guarantors of the Company’s loan agreement with Seaside Bank $ 522,746 $ 456,190 Accrued interest payable 777,937 580,204 Vendor accruals and other 79,138 79,132 Accrued expenses and other current liabilities $ 1,379,821 $ 1,115,526

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2020
Disclosure Text Block [Abstract]
Schedule of Debt [Table Text Block]	Notes payable were comprised of the following as of September 30, 2020 and December 31, 2019: September 30, December 31, Seaside Bank note payable $ 980,000 $ 980,000 Hunton & Williams note payable 387,500 391,000 Weider note payable 453,493 482,939 Mallard note payable 243,250 250,000 EIDL note payable 150,000 - Total notes payable 2,214,243 2,103,939 Less unamortized debt discount (43,592 ) (50,448 ) Total notes payable net of unamortized debt discount 2,170,651 2,053,491 Less current portion (1,400,910 ) (1,297,477 ) Long-term portion $ 769,741 $ 756,014

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	Officer and Director Notes September 30, December 31, Northstar $ 262,000 $ 262,000 Note payable, Mr. Tomas 161,786 161,786 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 178,077 178,077 Note payable, Mr. Tomas 187,500 - Note payable, Mr. Tomas 187,500 - Note payable, Mr. Tomas 500,000 - Note payable, Mr. Tomas 100,962 - Note payable, Dr. Comella* 255,579 255,579 Note payable, Dr. Comella* 300,000 300,000 Note payable, Dr. Comella* 300,000 300,000 Note payable, Dr. Comella* 300,000 300,000 Total officer and director notes $ 3,733,404 $ 2,757,442 * Dr. Comella is no longer a member of the Board of Directors effective September 1, 2019.

STOCKHOLDERS' DEFICIT (Tables)

STOCKHOLDERS' DEFICIT (Tables)	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
Share-based Payment Arrangement, Option, Activity [Table Text Block]	A summary of the stock option activity for the nine months ended September 30, 2020 is as follows: Weighted Weighted Average Average Number of Exercise Remaining Life Intrinsic Options Price In Years Value Outstanding, December 31, 2019 111,120,474 $ 0.0247 8.3 $ - Granted - Exercised - Forfeited/Expired (560 ) $ 0.1540 Outstanding, September 30, 2020 111,119,914 $ 0.0247 7.8 $ - Exercisable, September 30, 2020 75,737,414 $ 0.0255 7.2 $ -
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Weighted Weighted Outstanding Average Average Exercisable Average Exercise Number of Exercise Remaining Life Number of Exercise Price Options Price In Years Options Price $0.004 to $0.010 41,900,000 $ 0.0051 8.3 21,650,000 $ 0.0049 $0.011 to $0.020 16,300,000 $ 0.0196 6.0 16,300,000 $ 0.0196 $0.021 to $0.030 9,710,000 $ 0.0253 8.1 8,605,000 $ 0.0252 $0.0363 22,735,000 $ 0.0363 6.9 18,707,500 $ 0.0363 $0.0536 20,000,000 $ 0.0536 7.6 10,000,000 $ 0.0536 $0.1540 474,914 $ 0.1540 5.0 474,914 $ 0.1540 111,119,914 $ 0.0247 7.5 75,737,414 $ 0.0255
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the warrant activity for the nine months ended September 30, 2020 is as follows: Weighted Weighted Average Average Remaining Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2019 1,110,468 $ 12.8400 8.2 $ - Granted - Exercised - Expired - Outstanding, September 30, 2020 1,110,468 $ 12.84 7.4 $ - Exercisable, September 30, 2020 1,108,923 $ 2.14 7.4 $ -
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	Warrants Outstanding Warrants Exercisable Weighted Weighted Weighted Outstanding Average Average Exercisable Average Exercise Number of Exercise Remaining Life Number of Exercise Price Warrants Price In Years Warants Price $0.03 to $20.00 1,086,536 $ 1.27 7.5 1,086,536 $ 1.27 $20.01 to $30.00 19,543 $ 25.06 3.4 19,543 $ 25.06 $40.01 to $50.00 2,253 $ 48.83 2.0 2,253 $ 48.83 $50.01 to $60.00 543 $ 60.00 0.8 543 $ 60.00 >$60.00 1,593 $ 7,690.00 6.1 48 $ 7,690.00 1,110,468 $ 12.84 7.4 1,108,923 $ 2.14

CONCENTRATIONS (Tables)

CONCENTRATIONS (Tables)	9 Months Ended
	Sep. 30, 2020
Customer Concentration Risk [Member]
CONCENTRATIONS (Tables) [Line Items]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	For the three and nine months ended September 30, 2020 and 2019, the following customers accounted for more than 10% of the Company’s net revenues: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2020 2019 2020 2019 Customer 1 24 % - 15 % - Customer 2 15 % - - - Customer 3 14 % - - - Customer 4 - - 13 % - Customer 5 - 27 % - 12 % Customer 6 - 22 % - - Totals 53 % 49 % 28 % 12 %
Credit Concentration Risk [Member]
CONCENTRATIONS (Tables) [Line Items]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	As of September 30, 2020 and December 31, 2019, the following customers represented more than 10% of the Company’s accounts receivable: September 30, December 31, Customer 1 83 % 47 % Customer 2 - 47 % Totals 83 % 94 %

GOING CONCERN AND MANAGEMENT'_2

GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 81,228	$ 78,104	$ 81,228	$ 78,104		$ 0		$ 1,357,146
Working Capital (Deficit)	(10,349,510)		(10,349,510)
Net Income (Loss) Attributable to Parent	(1,155,775)	(1,645,949)	(2,300,809)	(3,158,293)
Net Cash Provided by (Used in) Operating Activities			(357,851)	(991,136)
Stockholders' Equity Attributable to Parent	$ (11,179,501)	$ (9,113,812)	$ (11,179,501)	$ (9,113,812)	$ (10,208,851)	$ (9,479,396)	$ (7,676,326)	$ (6,882,210)

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Sep. 01, 2019	Jan. 01, 2019	Jan. 30, 2018
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Accounts Receivable, Allowance for Credit Loss, Current	$ 13,203		$ 13,203
Deferred Revenue	83,250		83,250		$ 86,300
Research and Development Expense	$ 0	$ 0	$ 0	$ 263
Sunrise, Florida [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Operating Lease, Liability						$ 383,351	$ 57,000
Operating Lease, Right-of-Use Asset							$ 57,000
U.S. Stem Cell Clinic, LLC [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	49.90%		49.90%
U.S. Stem Cell Clinic of The Village LLC (the "LLC") [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	49.00%		49.00%					49.00%
Royalty Arrangement [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Deferred Revenue	$ 63,250		$ 63,250		$ 65,500

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	123,490,815	122,150,906
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	111,119,914	121,038,655
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,110,468	1,112,251
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	11,260,433	0

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Mar. 03, 2017	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Sale Leaseback Transaction, Lease Terms	Termination and Release Agreement and a Letter Agreement intended to divest itself of certain equipment and other assets underlying the related equipment lease transaction
Sale Leaseback Transaction, Deferred Gain, Gross	$ 386,535
Sale Leaseback Transaction, Current Period Gain Recognized		$ 0	$ 32,211	$ 21,474	$ 96,634
Sale Leaseback Transaction, Deferred Gain, Net		$ 0		0		$ 21,474
Depreciation			51,652	$ 0	154,956
Cost, Depreciation			$ 51,652		$ 154,956

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details) - Schedule of Property and Equipment - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Schedule of Property and Equipment [Abstract]
Furniture, fixtures and equipment	$ 5,598	$ 5,598
Computer equipment	1,809	1,809
Property and equipment, gross	7,407	7,407
Less accumulated depreciation and amortization	(7,407)	(7,407)
Property and equipment, net	$ 0	$ 0

INVESTMENTS (Details)

INVESTMENTS (Details) - USD ($)	Jan. 30, 2018	Jan. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2020	Jan. 29, 2019
INVESTMENTS (Details) [Line Items]
Income (Loss) from Equity Method Investments			$ (9,718)	$ (33,478)	$ (23,539)	$ 93,778
Equity Method Investments			0		0		$ 23,539		$ 0
Revenues			$ 64,647	156,591	$ 161,793	2,763,385
U.S. Stem Cell Clinic, LLC [Member]
INVESTMENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage			49.90%		49.90%				49.90%
Income (Loss) from Equity Method Investments			$ (9,718)	(51,514)	$ (23,539)	51,514			$ 599,921
Proceeds from Equity Method Investment, Distribution					0	64,870			663,870
Accounts Receivable, after Allowance for Credit Loss			28,763		28,763		28,763		28,763
Revenues			0	33,614	1,441	329,003
Investment Company, Contributed Capital, Percent		16.60%
Contribution to Equity		$ 4,435
Regenerative Wellness Clinic, LLC [Member]
INVESTMENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage										33.30%
Income (Loss) from Equity Method Investments				(2,910)	0	69,345			113,047
Proceeds from Equity Method Investment, Distribution					0	101,963			101,963
Equity Method Investments			$ 0		$ 0		0		$ 0
Accounts Receivable, after Allowance for Credit Loss							0
Revenues				16,637		132,984
Investment Company, Contributed Capital, Percent		16.60%
Contribution to Equity		$ 10,830
U.S. Stem Cell Clinic of The Village LLC (the "LLC") [Member]
INVESTMENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage	49.00%		49.00%		49.00%				49.00%
Income (Loss) from Equity Method Investments				(9,931)	$ 0	(27,081)			$ 23,050
Proceeds from Equity Method Investment, Distribution					0
Equity Method Investments			$ 0		0				0
Revenues				9,975	0	140,328
Related Party Transaction, Description of Transaction	To that end, U.S. Stem Cell Clinic of The Villages LLC (the “LLC”) was formed January 30, 2018. Knutson provided the Company with the sum of Three Hundred Thousand Dollars ($300,000) (the “Investment”) to be utilized for the formation and initial operation of the LLC. Currently, Knutson holds a 51% member interest in the LLC and the Company holds a 49% member interest. The Company will provide operating assistance as well as management services, the latter to be compensated at fee of five percent (5%) of the LLC gross revenues
Ownership Percentage by Knutson	51.00%
Proceeds from Contributed Capital							$ 86,750	$ 189,909
Accounts Receivable, before Allowance for Credit Loss			$ 0		0				$ 0
Proceeds from Fees Received				$ 975	$ 0	$ 50,751
U.S. Stem Cell Clinic of The Village LLC (the "LLC") [Member] | Utilized for Fromation of LLC [Member]
INVESTMENTS (Details) [Line Items]
Related Party Transaction, Amounts of Transaction	$ 300,000

RIGHT TO USE ASSETS AND LEASE_3

RIGHT TO USE ASSETS AND LEASE LIABILITY (Details)	Sep. 01, 2019USD ($)	Sep. 30, 2020USD ($)ft²	Dec. 31, 2019	Jan. 01, 2019USD ($)
RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Estimated Incremental Borrowing Rate			8.00%
Sunrise, Florida [Member]
RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Area of Land (in Square Feet) | ft²		4,860
Operating Leases, Annual Rent Amount	$ 87,674	$ 82,620
Operating Leases, Monthly Base Rent Amount		$ 7,306
Estimated Incremental Borrowing Rate	8.00%
Operating Lease, Liability	$ 383,351			$ 57,000
Operating Lease Right of Use Asset, Gross				274,180
Operating Lease, Right-of-Use Asset				57,000
Sunrise, Florida [Member] | Lease Escalation [Member]
RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Operating Leases, Annual Rent Amount	$ 98,678
Accounting Standards Update 2016-02 [Member] | Sunrise, Florida [Member]
RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Operating Lease, Liability				56,734
Operating Lease, Right-of-Use Asset				$ 56,734

RIGHT TO USE ASSETS AND LEASE_4

RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Lease, Cost - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Lease, Cost [Abstract]
Operating lease expense	$ 1,689	$ 34,560	$ 3,891	$ 105,200
Variable lease expense	0	0	0	685
Total lease expense	$ 1,689	$ 34,560	$ 3,891	$ 105,885

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($)	Oct. 07, 2015	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
ACCRUED EXPENSES (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	34,522			1,445,647
Debt Conversion, Converted Instrument, Amount				$ 11,565
Debt Conversion, Original Debt, Amount	$ 100,000			9,145
Gain (Loss) on Extinguishment of Debt		$ (204)	$ 33,203	277	$ 21,892
Notes Payable, Other Payables [Member]
ACCRUED EXPENSES (Details) [Line Items]
Gain (Loss) on Extinguishment of Debt				$ 2,420

ACCRUED EXPENSES (Details) - Sc

ACCRUED EXPENSES (Details) - Schedule of Accrued Liabilities - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Schedule of Accrued Liabilities [Abstract]
Interest and fees payable to the Guarantors of the Company’s loan agreement with Seaside Bank	$ 522,746	$ 456,190
Accrued interest payable	777,937	580,204
Vendor accruals and other	79,138	79,132
Accrued expenses and other current liabilities	$ 1,379,821	$ 1,115,526

NOTES PAYABLE (Details)

NOTES PAYABLE (Details)

Jun. 20, 2020USD ($)

Dec. 06, 2019USD ($)

Jun. 03, 2019USD ($)

Aug. 31, 2017USD ($)

Jun. 01, 2015

Sep. 30, 2020USD ($)

Sep. 30, 2019USD ($)

Mar. 31, 2018

Sep. 30, 2020USD ($)

Sep. 30, 2019USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2019USD ($)

Oct. 25, 2010

Seaside National Bank and Trust [Member] | Notes Payable to Banks [Member]

NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

4.25%

Debt Instrument, Maturity Date

May 18, 2020

Hunton & Williams Notes [Member] | Notes Payable, Other Payables [Member]

NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Number of Outstanding Notes Payable

2

Notes Payable

$ 387,500

$ 387,500

$ 391,000

Debt Instrument, Payment Terms

payable in one balloon payment upon the date of a written demand and upon certain triggering events occurring

payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar Biotech Group, LLC (or successor) Loan is paid off.

Other Notes Payable

$ 747,680

Accounts Payable, Other, Current

40,596

Notes and Loans Payable

$ 788,276

Debt Instrument, Description

The noteholder agreed to accept full payment of their obligation over a four (4) year period in 48 monthly installments on an adjusted debt obligation in aggregate of $624,000 (reducing the outstanding balance), with such payments staggered in amounts such that the Company will pay $10,000 monthly the first year, $12,000 monthly the second year, $14,000 monthly the third year, and $16,000 monthly the final year. In addition, the noteholder agreed to suspend accrual interest on the notes commencing September 1, 2017. The Agreement remains in full force and effect provided the Company continues to make the monthly payments, there is no event of default as defined in the notes and an agreement to a subordination agreement by Northstar Biotech Group, LLC, which has been provided. In May 2019, the Company did not make the required scheduled payment. In September 2010, the noteholder agreed to waive their default rights under the agreement provided a minimum of $5,000 was paid by the end of 2019 and to reduce the required monthly payment to $500 per month commencing in January 2020. The Company satisfied the $5,000 payment requirement by the end of 2019 and commenced making the required $500 monthly payments in January 2020.

Imputed Interest, Rate

5.00%

Debt Instrument, Unamortized Discount

$ 69,700

Amortization of Debt Discount (Premium)

$ 24,205

0

$ 34,945

Hunton & Williams Note #1 [Member] | Notes Payable, Other Payables [Member]

NOTES PAYABLE (Details) [Line Items]

Notes Payable

$ 61,150

Hunton & Williams Note #2 [Member] | Notes Payable, Other Payables [Member]

NOTES PAYABLE (Details) [Line Items]

Notes Payable

$ 323,822

Weider promissory note [Member] | Notes Payable, Other Payables [Member]

NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.25%

Notes Payable

453,493

453,493

482,939

Debt Instrument, Face Amount

$ 500,000

Debt Instrument, Periodic Payment

$ 5,000

Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Notes Payable, Other Payables [Member]

NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate Terms

non-interest bearing

Mallard Note Payable [Member] | Notes Payable, Other Payables [Member]

NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Notes Payable

199,658

199,658

199,551

Debt Instrument, Payment Terms

payable in monthly increments of $750 per month, with a final balloon payment of $205,000 due on January 1, 2025

Debt Instrument, Unamortized Discount

$ 51,063

43,592

43,592

$ 50,448

Amortization of Debt Discount (Premium)

2,328

6,857

Debt Instrument, Face Amount

$ 250,000

EIDL Note Payable [Member] | Notes Payable, Other Payables [Member]

NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

3.75%

Notes Payable

150,000

150,000

Debt Instrument, Payment Terms

monthly beginning June 20, 2021 (twelve months from the date of the SBA Loan Agreement) in the amount of $731. The balance of principal and interest is payable thirty years from the date of the SBA Loan Agreement

Debt Instrument, Face Amount

$ 150,000

Debt Instrument, Periodic Payment

$ 731

Interest Payable

$ 1,572

$ 1,572

NOTES PAYABLE (Details) - Sched

NOTES PAYABLE (Details) - Schedule of Debt - USD ($)	Sep. 30, 2020	Dec. 31, 2019	Dec. 06, 2019	Aug. 31, 2017
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross	$ 2,214,243	$ 2,103,939
Less unamortized debt discount	(43,592)	(50,448)
Total notes payable net of unamortized debt discount	2,170,651	2,053,491
Less current portion	(1,400,910)	(1,297,477)
Long term portion	769,741	756,014
Notes Payable, Other Payables [Member]
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Less unamortized debt discount	(34,091)	(41,391)
Seaside National Bank and Trust [Member] | Notes Payable to Banks [Member]
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross	980,000	980,000
Hunton & Williams Notes [Member] | Notes Payable, Other Payables [Member]
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross	387,500	391,000
Less unamortized debt discount				$ (69,700)
Weider promissory note [Member] | Notes Payable, Other Payables [Member]
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross	453,493	482,939
Mallard Note Payable [Member] | Notes Payable, Other Payables [Member]
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross	243,250	250,000
Less unamortized debt discount	(43,592)	(50,448)	$ (51,063)
EIDL Note Payable [Member] | Notes Payable, Other Payables [Member]
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross	$ 150,000	$ 0

PROMISSORY NOTE PAYABLE (Detail

PROMISSORY NOTE PAYABLE (Details) - Promissory Note [Member] - USD ($)	Jun. 01, 2020	Jun. 01, 2015	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
PROMISSORY NOTE PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount		$ 1,697,762
Debt Instrument, Periodic Payment		$ 75,000
Default Interest Rate	18.00%
Imputed Interest, Rate		5.00%
Debt Instrument, Unamortized Discount		$ 368,615	$ 0		$ 0		$ 29,296
Amortization of Debt Discount (Premium)			0	$ 17,616	29,295	$ 52,273
Notes Payable			$ 1,397,762		$ 1,397,762		$ 1,368,467
Unpaid Guarantor Fees [Member]
PROMISSORY NOTE PAYABLE (Details) [Line Items]
Debt Conversion, Original Debt, Amount		624,737
Principal [Member]
PROMISSORY NOTE PAYABLE (Details) [Line Items]
Debt Conversion, Original Debt, Amount		1,500,000
Interest [Member]
PROMISSORY NOTE PAYABLE (Details) [Line Items]
Debt Conversion, Original Debt, Amount		$ 373,469

CONVERTIBLE NOTE PAYABLE (Detai

CONVERTIBLE NOTE PAYABLE (Details) - USD ($)	Sep. 08, 2020	Feb. 05, 2020	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Jun. 15, 2019
CONVERTIBLE NOTE PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount	$ 10,000	$ 35,000					$ 500,000
Debt Instrument, Maturity Date		Feb. 5, 2021
Debt Instrument, Interest Rate, Stated Percentage	5.00%	5.00%					5.25%
Debt Instrument, Convertible, Terms of Conversion Feature		right to convert the outstanding balance of the note at any time into shares of common stock of the Company at a conversion price equal to a thirty percent (30%) discount of the average closing price of the Company’s common stock on the OTC Markets electronic exchange for the prior thirty (30) trading days prior to conversion
Debt Instrument, Unamortized Discount			$ 43,592	$ 43,592		$ 50,448
Amortization of Debt Discount (Premium)				309,219	$ 141,296
Convertible Notes Payable	$ 10,000		28,779	28,779
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	$ 0.0467
Default Interest Rate	18.00%
Convertible Notes Payable [Member]
CONVERTIBLE NOTE PAYABLE (Details) [Line Items]
Debt Instrument, Unamortized Discount		$ 15,000	6,221	6,221
Amortization of Debt Discount (Premium)			3,777	8,779
Interest Payable			1,141	1,141
Convertible Debt [Member]
CONVERTIBLE NOTE PAYABLE (Details) [Line Items]
Interest Payable			$ 30	$ 30

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)		Apr. 01, 2020	Feb. 05, 2020	Oct. 09, 2019	Oct. 01, 2019	Jul. 01, 2019	Oct. 19, 2018	May 07, 2018	Apr. 19, 2018	Oct. 02, 2017	Aug. 07, 2017	Apr. 01, 2017	Mar. 09, 2017	Mar. 03, 2017	Nov. 09, 2016	Oct. 06, 2016	Apr. 07, 2016	Oct. 07, 2015	Oct. 02, 2015	Apr. 03, 2015	Oct. 03, 2014	Apr. 02, 2014	Dec. 24, 2013	Sep. 30, 2013	Oct. 01, 2012	Sep. 21, 2012	Mar. 30, 2012	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2013	Sep. 08, 2020	Jul. 01, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 15, 2019	Sep. 06, 2016	Dec. 31, 2015	Feb. 28, 2013	Feb. 29, 2012
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due to Related Parties, Current																												$ 797,040		$ 797,040							$ 511,744
Debt Instrument, Face Amount			$ 35,000																														$ 10,000					$ 500,000
Class of Warrant or Rights, Granted (in Shares)																														0
Percentage of Revenues to be Received as Royalty															5.00%
Debt Instrument, Interest Rate, Stated Percentage			5.00%																														5.00%					5.25%
Preferred Stock, Shares Authorized (in Shares)																												20,000,000		20,000,000							20,000,000			20,000,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares)																		34,522												1,445,647
Debt Conversion, Original Debt, Amount																		$ 100,000												$ 9,145
Debt Conversion, Converted Instrument, Amount																														11,565
Stock Issued During Period, Value, Other																												$ 10,205	$ 34,013	44,368	$ 312,194
Gain (Loss) on Extinguishment of Debt																												(204)	$ 33,203	277	21,892
Notes Payable, Related Parties																												3,733,404		3,733,404							$ 2,757,442
Repayments of Notes Payable																														39,697	381,000
Repayments of Related Party Debt																														0	213,739
Debt Instrument, Maturity Date			Feb. 5, 2021
Sale Leaseback Transaction, Lease Terms														Termination and Release Agreement and a Letter Agreement intended to divest itself of certain equipment and other assets underlying the related equipment lease transaction
Accrued Marketing Costs, Current																												0		0
Proceeds from Sale of Machinery and Equipment														$ 50,000
Officers and Directors [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Proceeds from Related Party Debt																														285,296	140,000
Due to Related Parties, Current																												797,040		797,040							511,744
Series A Preferred Stock [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Preferred Stock, Voting Rights																									modify the voting rights of the subsequently cancelled Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stockholders to 25 votes per share on matters to be voted on by the common stockholders and all prior and subsequent payments of interest will be in common stock
Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Gain (Loss) on Extinguishment of Debt																														2,420
Notes Payable, Other Payables [Member] | Affiliated Entity [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																										$ 544,267
Debt Instrument, Payment Terms																									Company was obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six-month anniversary of the effective date (October 1, 2012).		agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May 1, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement. The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.
Class of Warrant or Rights, Granted (in Shares)																										5,000
Debt Instrument, Debt Default, Description of Violation or Event of Default																									entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 shares of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights. In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing, and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.
Percentage of Revenues to be Received as Royalty																									8.00%
Debt Instrument, Interest Rate, Stated Percentage																									12.85%																7.00%
Debt Conversion, Converted Instrument, Shares Issued (in Shares)		1,445,647			1,692,353		164,523		379,141	559,187		286,315											3,916	8,772
Debt Conversion, Original Debt, Amount		$ 9,145			$ 9,195		$ 9,195		$ 9,145	$ 12,705		$ 12,703											$ 85,447	$ 100,000
Debt Conversion, Converted Instrument, Amount		11,565
Gain (Loss) on Extinguishment of Debt		$ 2,420
Notes Payable, Related Parties																												262,000		262,000
Interest Expense, Related Party																														13,323
Interest Payable																																					8,700
Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Interest Payable																												453,282		453,282							389,695
Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Interest Payable																												194,081		194,081							150,708
Notes Payable, Other Payables [Member] | Series A Preferred Stock [Member] | Affiliated Entity [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Value, Other																																$ 316,800
Interest [Member] | Notes Payable, Other Payables [Member] | Affiliated Entity [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)																848,490	57,778		4,156	1,363	515	275
Debt Conversion, Original Debt, Amount																$ 12,705			$ 12,705	$ 12,635	$ 12,705	$ 12,635
Debt Conversion, Converted Instrument, Amount																	$ 12,705
Note Payable #5 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount											$ 500,000
Debt Instrument, Interest Rate, Stated Percentage											5.00%
Notes Payable, Related Parties																												161,786		161,786							161,786
Repayments of Notes Payable																														0	321,607
Note Payable #5 [Member] | Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage						5.00%
Notes Payable, Related Parties	[1]																											300,000		300,000							300,000
Notes Payable, Related Parties, Noncurrent						$ 300,000
Debt Instrument, Maturity Date						Nov. 7, 2019
Notes Receivable, Related Parties																												300,000		300,000
Note Payable #6 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount								$ 500,000
Debt Instrument, Interest Rate, Stated Percentage								5.00%
Notes Payable, Related Parties																												500,000		500,000							500,000
Debt Instrument, Term								6 months
Note Payable #7 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount						$ 500,000
Debt Instrument, Interest Rate, Stated Percentage						5.00%
Notes Payable, Related Parties																												500,000		500,000							$ 500,000
Note Payable #8 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																																					5.00%
Notes Payable, Related Parties																												178,077		178,077							$ 178,077
Note Payable #9 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																				$ 187,500
Debt Instrument, Interest Rate, Stated Percentage																																				5.00%
Notes Payable, Related Parties																												187,500		187,500							0
Note Payable #10 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																			$ 187,500
Debt Instrument, Interest Rate, Stated Percentage																																			5.00%
Notes Payable, Related Parties																												187,500		187,500							0
Note Payable #11 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																		$ 500,000
Debt Instrument, Interest Rate, Stated Percentage																																		5.00%
Notes Payable, Related Parties																												500,000		500,000							0
Note Payable #12 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																												$ 100,962		$ 100,962
Debt Instrument, Interest Rate, Stated Percentage																												5.00%		5.00%
Notes Payable, Related Parties																												$ 100,962		$ 100,962							0
Note Payable #2 [Member] | Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																							$ 300,000
Debt Instrument, Interest Rate, Stated Percentage																																							5.00%
Notes Payable, Related Parties	[1]																											255,579		255,579							255,579
Repayments of Related Party Debt																															$ 107,868
Note Payable #3 [Member] | Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount											$ 300,000
Debt Instrument, Interest Rate, Stated Percentage											5.00%
Notes Payable, Related Parties	[1]																											300,000		300,000							300,000
Debt Instrument, Term											1 year
Note Payable #4 [Member] | Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount								$ 300,000
Debt Instrument, Interest Rate, Stated Percentage								5.00%
Notes Payable, Related Parties	[1]																											$ 300,000		$ 300,000							$ 300,000
Debt Instrument, Term								6 months
GACP Stem Cell Bank, LLC [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Gain (Loss) on Extinguishment of Debt				$ 100,000
Sale Leaseback Transaction, Net Book Value														$ 400,000
Sale Leaseback Transaction, Lease Terms														leased back the sold equipment over a three-year term
Percentage of Renenue Accrued for Marketing														10.00%
Sale Leaseback Transaction, Description														Company also entered into a customer purchase agreement with GACP whereby the Company received a deposit $50,000 (included in long-term liabilities at December 31, 2018) in exchange for the sale of the first 5,000 future customers of the cell-banking business after the effective date of the agreement; GACP also had the right to purchase additional customers at a price of $20 per customer. There is no reduction in the selling price should the new customers be fewer than 5,000
Proceeds from Sale of Intangible Assets														$ 50,000
Northstar Claims [Member] | Stock Issued for Conversion of Series A Preferred Stock and Litigation Case [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)												1,000,000	30,000,000
[1]	Dr. Comella is no longer a member of the Board of Directors effective September 1, 2019.

RELATED PARTY TRANSACTIONS (D_2

RELATED PARTY TRANSACTIONS (Details) - Schedule of Related Party Transactions - USD ($)		Sep. 30, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Notes Payable, Related Party		$ 3,733,404	$ 2,757,442
Northstar Claims [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party		262,000	262,000
Note Payable #5 [Member] | Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party		161,786	161,786
Note Payable #5 [Member] | Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	[1]	300,000	300,000
Note Payable #6 [Member] | Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party		500,000	500,000
Note Payable #7 [Member] | Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party		500,000	500,000
Note Payable #8 [Member] | Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party		178,077	178,077
Note Payable #9 [Member] | Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party		187,500	0
Note Payable #10 [Member] | Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party		187,500	0
Note Payable #11 [Member] | Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party		500,000	0
Note Payable #12 [Member] | Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party		100,962	0
Note Payable #2 [Member] | Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	[1]	255,579	255,579
Note Payable #3 [Member] | Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	[1]	300,000	300,000
Note Payable #4 [Member] | Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	[1]	$ 300,000	$ 300,000
[1]	Dr. Comella is no longer a member of the Board of Directors effective September 1, 2019.

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Dec. 06, 2019	Jun. 15, 2019	Jul. 01, 2018	Nov. 09, 2016	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2020	Sep. 08, 2020	Feb. 05, 2020	Dec. 31, 2019
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Royalty Agreement, Term				25 years
Revenue from Contract with Customer, Including Assessed Tax				$ 75,000
Percentage of Revenues to be Received as Royalty				5.00%
Deferred Revenue							$ 83,250			$ 86,300
Debt Instrument, Face Amount		$ 500,000						$ 10,000	$ 35,000
General Insurance Expense					$ 11,000	$ 100,000
Settlement Liabilities, Current							28,850			30,050
Debt Instrument, Interest Rate, Stated Percentage		5.25%						5.00%	5.00%
Debt Instrument, Periodic Payment		$ 5,000
Mallard Note Payable [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Debt Instrument, Face Amount	$ 250,000
Debt Instrument, Payment Terms	payable in monthly increments of $750 per month, with a final balloon payment of $205,000 due on January 1, 2025
Bonus [Member] | Chief Executive Officer [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Deferred Compensation Arrangement with Individual, Description			any liability, and as part of that Agreement, the Company agreed to provide a five-year 5.25% Promissory Note, dated June 15, 2019, in the principal amount of Five Hundred Thousand Dollars ($500,000), payable in monthly increments of Five Thousand ($5,000) per month
Royalty Arrangement [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Deferred Revenue							$ 63,250			$ 65,500

STOCKHOLDERS' DEFICIT (Details)

STOCKHOLDERS' DEFICIT (Details) - USD ($)	May 07, 2018	Aug. 07, 2017	Apr. 21, 2017	Sep. 16, 2016	Oct. 07, 2015	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Nov. 02, 2015	Aug. 04, 2014	Apr. 01, 2013
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Value, Other						$ 10,205	$ 34,013	$ 44,368	$ 312,194
Gain (Loss) on Extinguishment of Debt						(204)	$ 33,203	$ 277	21,892
Debt Conversion, Converted Instrument, Shares Issued (in Shares)					34,522			1,445,647
Debt Conversion, Converted Instrument, Amount								$ 11,565
Debt Conversion, Original Debt, Amount					$ 100,000			$ 9,145
Stock Issued During Period, Shares, Issued for Services (in Shares)								4,000,000
Stock Issued During Period, Value, Issued for Services								$ 16,000	86,350
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value										$ 0
Share-based Payment Arrangement, Noncash Expense								541,336	586,382
Aggregate Intrinsic Value of the Issued and Exercisable Warrants								0
Notes Payable, Other Payables [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Gain (Loss) on Extinguishment of Debt								$ 2,420
Accounts Payable [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)								6,532,248
Stock Issued During Period, Value, Other								$ 32,803
Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Gain (Loss) on Extinguishment of Debt								2,697
Share-based Payment Arrangement, Option [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value						$ 0		$ 0
Share Price (in Dollars per share)						$ 0.0043		$ 0.0043
Share-based Payment Arrangement, Noncash Expense								$ 525,336	$ 512,882
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount						$ 890,216		$ 890,216
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition								335 days
Bioheart 2013 Omnibus Equity Compensation Plan [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)											500,000,000	100,000	50,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in Shares)	100,000,000	30,000,000	25,000,000	25,000,000

STOCKHOLDERS' DEFICIT (Detail_2

STOCKHOLDERS' DEFICIT (Details) - Share-based Payment Arrangement, Option, Activity - USD ($)	Dec. 31, 2019	Sep. 30, 2020
Share-based Payment Arrangement, Option, Activity [Abstract]
Options Outstanding	111,120,474
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 0.0247
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years 109 days	7 years 292 days
Options Outstanding, Intrinsic Value (in Dollars)	$ 0
Options exercisable		75,737,414
Options exercisable, Weighted-Average Exercise Price (in Dollars per share)		$ 0.0255
Options exercisable, Weighted-Average Remaining Contractual Term		7 years 73 days
Options Granted		0
Options Exercised		0
Options Forfeited/Expired		(560)
Options Forfeited/Expired, Weighted-Average Exercise Price (in Dollars per share)		$ 0.1540
Options Outstanding		111,119,914
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)		$ 0.0247

STOCKHOLDERS' DEFICIT (Detail_3

STOCKHOLDERS' DEFICIT (Details) - Share-based Payment Arrangement, Option, Exercise Price Range	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Weighted-Average Exercise Price	$ 0.0247
Options Outstanding, Weighted-Average Remaining Contractual Term	7 years 6 months
Options Outstanding (in Shares) | shares	111,119,914
Options Exercisable (in Shares) | shares	75,737,414
Options Exercisable, Weighted-Average Exercise Price	$ 0.0255
Options $0.000 to $0.010 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Weighted-Average Exercise Price	$ 0.0051
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years 109 days
Options Outstanding (in Shares) | shares	41,900,000
Options Exercisable (in Shares) | shares	21,650,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.0049
Options $0.000 to $0.010 [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.004
Options $0.000 to $0.010 [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.010
Options $0.011 to $0.020 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Weighted-Average Exercise Price	$ 0.0196
Options Outstanding, Weighted-Average Remaining Contractual Term	6 years
Options Outstanding (in Shares) | shares	16,300,000
Options Exercisable (in Shares) | shares	16,300,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.0196
Options $0.011 to $0.020 [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.011
Options $0.011 to $0.020 [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.020
Options $0.021 to $0.030 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Weighted-Average Exercise Price	$ 0.0253
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years 36 days
Options Outstanding (in Shares) | shares	9,710,000
Options Exercisable (in Shares) | shares	8,605,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.0252
Options $0.021 to $0.030 [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.021
Options $0.021 to $0.030 [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.030
Options $0.0363 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.0363
Options Outstanding, Weighted-Average Exercise Price	$ 0.0363
Options Outstanding, Weighted-Average Remaining Contractual Term	6 years 328 days
Options Outstanding (in Shares) | shares	22,735,000
Options Exercisable (in Shares) | shares	18,707,500
Options Exercisable, Weighted-Average Exercise Price	$ 0.0363
Options, $0.0536 Exercise Price [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.0536
Options Outstanding, Weighted-Average Exercise Price	$ 0.0536
Options Outstanding, Weighted-Average Remaining Contractual Term	7 years 219 days
Options Outstanding (in Shares) | shares	20,000,000
Options Exercisable (in Shares) | shares	10,000,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.0536
Options $0.1540 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.1540
Options Outstanding, Weighted-Average Exercise Price	$ 0.1540
Options Outstanding, Weighted-Average Remaining Contractual Term	5 years
Options Outstanding (in Shares) | shares	474,914
Options Exercisable (in Shares) | shares	474,914
Options Exercisable, Weighted-Average Exercise Price	$ 0.1540

STOCKHOLDERS' DEFICIT (Detail_4

STOCKHOLDERS' DEFICIT (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]
Warrants Outstanding		1,110,468
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share)		$ 12.8400
Warrants Outstanding, Weighted-Average Remaining Contractual Term	7 years 146 days	8 years 73 days
Warrants Exercisable	1,108,923
Warrants Exercisable, Weighted-Average Exercise Price (in Dollars per share)	$ 2.14
Warrants Exercisable, Weighted-Average Remaining Contractual Term	7 years 146 days
Warrants Issued	0
Warrants Exercised	0
Warrants Expired	0
Warrants Outstanding	1,110,468
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 12.84

STOCKHOLDERS' DEFICIT (Detail_5

STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Shares	1,110,468		1,110,468
Warrants Outstanding, Weighted- Average Exercise Price	$ 12.84
Warrants Outstanding, Weighted- Average Remaining Contractual Term	7 years 146 days	8 years 73 days
Warrants Exercisable, Shares	1,108,923
Warrants Exercisable, Weighted- Average Exercise Price	$ 2.14
Class of Warrants or Rights, Exercise Price Range, $0.01-$20.00 [Member]
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Shares	1,086,536
Warrants Outstanding, Weighted- Average Exercise Price	$ 1.27
Warrants Outstanding, Weighted- Average Remaining Contractual Term	7 years 6 months
Warrants Exercisable, Shares	1,086,536
Warrants Exercisable, Weighted- Average Exercise Price	$ 1.27
Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member]
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Shares	19,543
Warrants Outstanding, Weighted- Average Exercise Price	$ 25.06
Warrants Outstanding, Weighted- Average Remaining Contractual Term	3 years 146 days
Warrants Exercisable, Shares	19,543
Warrants Exercisable, Weighted- Average Exercise Price	$ 25.06
Class of Warrants or Rights, Exercise Price Range, $40.01-$50.00 [Member]
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Shares	2,253
Warrants Outstanding, Weighted- Average Exercise Price	$ 48.83
Warrants Outstanding, Weighted- Average Remaining Contractual Term	2 years
Warrants Exercisable, Shares	2,253
Warrants Exercisable, Weighted- Average Exercise Price	$ 48.83
Class of Warrants or Rights, Exercise Price Range, $50.01-$60.00 [Member]
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Shares	543
Warrants Outstanding, Weighted- Average Exercise Price	$ 60
Warrants Outstanding, Weighted- Average Remaining Contractual Term	292 days
Warrants Exercisable, Shares	543
Warrants Exercisable, Weighted- Average Exercise Price	$ 60
Class of Warrants or Rights, Exercise Price Range, Greater than $60.00 [Member]
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Shares	1,593
Warrants Outstanding, Weighted- Average Exercise Price	$ 7,690
Warrants Outstanding, Weighted- Average Remaining Contractual Term	6 years 36 days
Warrants Exercisable, Shares	48
Warrants Exercisable, Weighted- Average Exercise Price	$ 7,690

CONCENTRATIONS (Details)

CONCENTRATIONS (Details)	Sep. 30, 2020
Customer Concentration Risk [Member] | Customer Five [Member] | Revenue Benchmark [Member]
CONCENTRATIONS (Details) [Line Items]
Equity Method Investment, Ownership Percentage	49.90%
Credit Concentration Risk [Member] | Customer One [Member] | Accounts Receivable [Member]
CONCENTRATIONS (Details) [Line Items]
Equity Method Investment, Ownership Percentage	49.90%

CONCENTRATIONS (Details) - Sche

CONCENTRATIONS (Details) - Schedules of Customer Concentration Risk - Customer Concentration Risk [Member] - Revenue Benchmark [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Concentration Risk [Line Items]
Customer Concentration Risk, Percentage	53.00%	49.00%	28.00%	12.00%
Customer One [Member]
Concentration Risk [Line Items]
Customer Concentration Risk, Percentage	24.00%	0.00%	15.00%	0.00%
Customer Two [Member]
Concentration Risk [Line Items]
Customer Concentration Risk, Percentage	15.00%	0.00%	0.00%	0.00%
Customer Three [Member]
Concentration Risk [Line Items]
Customer Concentration Risk, Percentage	14.00%	0.00%	0.00%	0.00%
Customer Four [Member]
Concentration Risk [Line Items]
Customer Concentration Risk, Percentage	0.00%	0.00%	13.00%	0.00%
Customer Five [Member]
Concentration Risk [Line Items]
Customer Concentration Risk, Percentage	0.00%	27.00%	0.00%	12.00%
Customer Six [Member]
Concentration Risk [Line Items]
Customer Concentration Risk, Percentage	0.00%	22.00%	0.00%	0.00%

CONCENTRATIONS (Details) - Sc_2

CONCENTRATIONS (Details) - Schedules of Credit Concentration Risk - Credit Concentration Risk [Member] - Accounts Receivable [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Concentration Risk [Line Items]
Credit Concentration Risk, Percentage	83.00%	94.00%
Customer One [Member]
Concentration Risk [Line Items]
Credit Concentration Risk, Percentage	83.00%	47.00%
Customer Two [Member]
Concentration Risk [Line Items]
Credit Concentration Risk, Percentage	0.00%	47.00%